<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>RISEDRONATE SODIUM- risedronate sodium hemi-pentahydrate and risedronate sodium monohydrate tablet, delayed release </strong><br>Actavis Pharma, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">
<span class="Bold">These highlights do not include all the information needed to use </span><span class="Bold">Risedronate sodium </span><span class="Bold"> </span><span class="Bold">safely and effectively. </span><span class="Bold">See full prescribing information for</span><span class="Bold"> </span><span class="Bold">Risedronate sodium</span><span class="Bold">. </span><br><span class="Bold">R</span><span class="Bold">isedronate sodium delayed-release tablets</span><br><span class="Bold">Initial U.S. Approval: </span><span class="Bold">1998</span><br>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><p class="Highlighta">Contraindications (<a href="#_4_CONTRAINDICATIONS">4</a>) 
		     
	
		     
	
		     
	
		     
	
		     
	03/2015<br>Warnings and Precautions (<a href="#_5_4_Jaw_Osteonecrosis">5.4</a>)                04/2015 </p></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Risedronate sodium is a bisphosphonate in a delayed-release formulation and is indicated for treatment of postmenopausal <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> (<a href="#_1_1_Postmenopausal_Osteoporosis">1.1</a>)  </p>
<p class="Highlighta">Limitations of Use </p>
<p class="Highlighta">Optimal duration of use has not been determined. For patients at low-risk for <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span>, consider drug discontinuation after 3 to 5 years of use (<a href="#_1_2__Important">1.2</a>) </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta">One 35 mg delayed-release tablet once-a-week (<a href="#_2_1_Treatment_of">2.1</a>) </p>
<p class="Highlighta">Instruct patients to: </p>
<ul class="Disc">
<li>Take Risedronate sodium  in the morning immediately <span class="Italics">following breakfast</span> with at least 4 ounces of plain water (<a href="#_2_2_Important_Administration">2.2</a>) <br>
</li>
<li>Avoid lying down for 30 minutes after taking Risedronate sodium  (<a href="#_2_2_Important_Administration">2.2</a>)<br>
</li>
<li>Take supplemental calcium and vitamin D if dietary intake is inadequate (<a href="#_2_3__Recommendations">2.3</a>)</li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Delayed-release tablets: 35 mg (<a href="#_3_DOSAGE_FORMS">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc">
<li>Abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia (<a href="#_4_CONTRAINDICATIONS">4</a>, <a href="#_5_2__Upper">5.2</a>) <br>
</li>
<li>Inability to stand or sit upright for at least 30 minutes (<a href="#_4_CONTRAINDICATIONS">4</a>, <a href="#_5_2__Upper">5.2</a>)<br>
</li>
<li><span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span> (<a href="#_4_CONTRAINDICATIONS">4</a>, <a href="#_5_3_Mineral_Metabolism">5.3</a>)<br>
</li>
<li>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any component of this product (<a href="#_4_CONTRAINDICATIONS">4</a>, <a href="#_6_2_Postmarketing_Experience">6.2</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>
<span class="Italics">Products Containing Same Active Ingredient</span>: Patients receiving Actonel should not be treated with Risedronate sodium  (<a href="#_5_1_Drug_Products">5.1</a>)<br>
</li>
<li>
<span class="Italics">Upper Gastrointestinal Adverse Reactions</span> can occur. Instruct patients to follow dosing instructions. Discontinue use if new or worsening symptoms occur (<a href="#_5_2__Upper">5.2</a>) <br>
</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span></span> may worsen and must be corrected prior to use (<a href="#_5_3_Mineral_Metabolism">5.3</a>)<br>
</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="77650" conceptname="Aseptic necrosis of bone">Osteonecrosis</span> of the </span><span class="Italics">J</span><span class="Italics">aw</span> has been reported (<a href="#_5_4_Jaw_Osteonecrosis">5.4</a>)<br>
</li>
<li>
<span class="Italics">Severe </span><span class="Italics">B</span><span class="Italics">one, </span><span class="Italics">J</span><span class="Italics">oint, </span><span class="Italics">M</span><span class="Italics">uscle </span><span class="Italics">P</span><span class="Italics">ain</span> may occur. Discontinue use if severe symptoms develop<span class="Bold"> </span>(<a href="#_5_5_Musculoskeletal_Pain">5.5</a>, <a href="#_6_2_Postmarketing_Experience">6.2</a>)<br>
</li>
<li>
<span class="Italics">Atypical </span><span class="Italics">F</span><span class="Italics">emur </span><span class="Italics">F</span><span class="Italics">ractures</span> have been reported. Patients with new thigh or <span class="product-label-link" type="condition" conceptid="4010361" conceptname="Inguinal pain">groin pain</span> should be evaluated to rule out a femoral <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> (<a href="#_5_6__Atypical">5.6</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions (greater than 5%) include: <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (<a href="#_6_1_Clinical_Studies">6.1</a>) </p>
<p class="Highlighta"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> (<span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, generalized <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, bullous <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>), and <span class="product-label-link" type="condition" conceptid="376709" conceptname="Discharge of eye">eye inflammation</span> (<span class="product-label-link" type="condition" conceptid="4274964" conceptname="Iritis">iritis</span>, <span class="product-label-link" type="condition" conceptid="4028363" conceptname="Uveitis">uveitis</span>) have been reported rarely (<a href="#_6_2_Postmarketing_Experience">6.2</a>) </p>
<p class="Highlighta"><span class="Bold"><br><br>To report SUSPECTED ADVERSE REACTIONS, contact Actavis at 1-800-272-5525 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch</span> </p>
</div>
<div><div></div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><p class="Highlighta">Calcium supplements, antacids, proton pump inhibitors (PPIs), H<span class="Sub">2</span> blockers, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of Risedronate sodium  (<a href="#_7_1_Calcium_Supplements_Antacids">7.1</a>, <a href="#_7_2_Histamine_2">7.2</a>) </p></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div>
<p class="Highlighta">Risedronate sodium is not recommended for use in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance less than 30 mL/min) (<a href="#_5_6_Renal_Impairment">5.6</a>, <a href="#_8_6_Renal_Impairment">8.6</a>, <a href="#_12_3_Pharmacokinetics">12.3</a>)  </p>
<p class="Highlighta">Risedronate sodium is not indicated for use in pediatric patients (<a href="#_8_4_Pediatric_Use">8.4</a>) </p>
<p class="Highlighta">        </p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div><div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 4/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"><span class="Bold">1</span><span class="Bold">
		     
	INDICATIONS AND USAGE</span></a></h1>
<h2><a href="#section-1.1" class="toc"><span class="Bold">1.1</span><span class="Bold">
		     
	Postmenopausal <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">Osteoporosis</span></span></a></h2>
<h2><a href="#section-1.2" class="toc"><span class="Bold">1.2 </span><span class="Bold">
		     
	Important Limitations of Use</span></a></h2>
<h1><a href="#section-2" class="toc"><span class="Bold">2</span><span class="Bold">
		     
	DOSAGE AND ADMINISTRATION</span></a></h1>
<h2><a href="#section-2.1" class="toc"><span class="Bold">2.1</span><span class="Bold">
		     
	Treatment</span><span class="Bold"> of Postmenopausal <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">Osteoporosis</span></span></a></h2>
<h2><a href="#section-2.2" class="toc"><span class="Bold">2.</span><span class="Bold">2</span>
		     
	<span class="Bold">Important Administration Instructions</span></a></h2>
<h2><a href="#section-2.3" class="toc"><span class="Bold">2.3 </span>
		     
	<span class="Bold">Recommendations for Calcium and Vitamin D Supplementation</span></a></h2>
<h2><a href="#section-2.4" class="toc"><span class="Bold">2.4 </span><span class="Bold"> Administration Instructions for Missed Doses </span></a></h2>
<h1><a href="#section-3" class="toc"><span class="Bold">3</span><span class="Bold">
		     
	DOSAGE FORMS AND STRENGTHS</span></a></h1>
<h1><a href="#section-4" class="toc"><span class="Bold">4</span>
		     
	<span class="Bold">CONTRAINDICATIONS</span></a></h1>
<h1><a href="#section-5" class="toc"><span class="Bold">5</span>
		     
	<span class="Bold">WARNINGS AND PRECAUTIONS</span></a></h1>
<h2><a href="#section-5.1" class="toc"><span class="Bold">5.1</span>
		     
	<span class="Bold">Drug Products with the Same Active Ingredient</span></a></h2>
<h2><a href="#section-5.2" class="toc"><span class="Bold">5.</span><span class="Bold">2 </span>
		     
	<span class="Bold">Upper Gastrointestinal </span><span class="Bold">Adverse Reactions</span></a></h2>
<h2><a href="#section-5.3" class="toc"><span class="Bold">5.</span><span class="Bold">3</span>
		     
	<span class="Bold">Mineral Metabolism</span></a></h2>
<h2><a href="#section-5.4" class="toc"><span class="Bold">5.</span><span class="Bold">4</span>
		     
	<span class="Bold">J</span><span class="Bold">aw</span><span class="Bold"> <span class="product-label-link" type="condition" conceptid="77650" conceptname="Aseptic necrosis of bone">Osteonecrosis</span></span></a></h2>
<h2><a href="#section-5.5" class="toc"><span class="Bold">5.</span><span class="Bold">5</span>
		     
	<span class="Bold"><span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">Musculoskeletal Pain</span></span></a></h2>
<h2><a href="#section-5.6" class="toc"><span class="Bold">5.6 </span><span class="Bold">
		     
	Atypical Subtrochanteric and Diaphyseal Femoral <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fractures</span></span></a></h2>
<h2><a href="#section-5.7" class="toc"><span class="Bold">5.</span><span class="Bold">7</span>
		     
	<span class="Bold">Renal I</span><span class="Bold">mpairment</span></a></h2>
<h2><a href="#section-5.8" class="toc"><span class="Bold">5.</span><span class="Bold">8</span><span class="Bold">
		     
	Laboratory Test Interactions</span></a></h2>
<h1><a href="#section-6" class="toc"><span class="Bold">6</span>
		     
	<span class="Bold">ADVERSE REACTIONS</span></a></h1>
<h2><a href="#section-6.1" class="toc"><span class="Bold">6.1</span>
		     
	<span class="Bold">Clinical Studies Experience</span></a></h2>
<h2><a href="#section-6.2" class="toc"><span class="Bold">6.</span><span class="Bold">2</span><span class="Bold">
		     
	Postmarketing Experience</span></a></h2>
<h1><a href="#section-7" class="toc"><span class="Bold">7</span>
		     
	<span class="Bold">DRUG INTERACTIONS</span></a></h1>
<h2><a href="#section-7.1" class="toc"><span class="Bold">7.1</span>
		     
	<span class="Bold">Calcium Supplements/Antacids</span></a></h2>
<h2><a href="#section-7.2" class="toc"><span class="Bold">7.2</span><span class="Bold">
		     
	Histamine 2 (H</span><span class="Bold"><span class="Sub">2</span></span><span class="Bold">) Blockers and Proton Pump Inhibitors (PPIs)</span></a></h2>
<h2><a href="#section-7.3" class="toc"><span class="Bold">7.</span><span class="Bold">3</span>
		     
	<span class="Bold">Hormone Therapy</span></a></h2>
<h2><a href="#section-7.4" class="toc"><span class="Bold">7.</span><span class="Bold">4</span><span class="Bold"> </span><span class="Bold">
		     
	Aspirin/Nonsteroidal Anti-Inflammatory Drugs</span></a></h2>
<h1><a href="#section-8" class="toc"><span class="Bold">8</span>
		     
	<span class="Bold">USE IN SPECIFIC POPULATIONS</span></a></h1>
<h2><a href="#section-8.1" class="toc"><span class="Bold">8.1</span>
		     
	<span class="Bold">Pregnancy</span></a></h2>
<h2><a href="#section-8.2" class="toc"><span class="Bold">8.3</span>
		     
	<span class="Bold">Nursing </span><span class="Bold">Mothers</span></a></h2>
<h2><a href="#section-8.3" class="toc"><span class="Bold">8.4</span>
		     
	<span class="Bold">Pediatric Use</span></a></h2>
<h2><a href="#section-8.4" class="toc"><span class="Bold">8.5</span>
		     
	<span class="Bold">Geriatric Use</span></a></h2>
<h2><a href="#section-8.5" class="toc"><span class="Bold">8.6</span><span class="Bold">
		     
	<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></a></h2>
<h2><a href="#section-8.6" class="toc"><span class="Bold">8.7</span><span class="Bold">
		     
	<span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></a></h2>
<h1><a href="#section-9" class="toc"><span class="Bold">10</span>
		     
	<span class="Bold">OVERDOSAGE</span></a></h1>
<h1><a href="#section-10" class="toc"><span class="Bold">11</span>
		     
	<span class="Bold">DESCRIPTION</span></a></h1>
<h1><a href="#section-11" class="toc"><span class="Bold">12</span>
		     
	<span class="Bold">CLINICAL PHARMACOLOGY</span></a></h1>
<h2><a href="#section-11.1" class="toc"><span class="Bold">12.1</span>
		     
	<span class="Bold">Mechanism of Action</span></a></h2>
<h2><a href="#section-11.2" class="toc"><span class="Bold">12.2</span>
		     
	<span class="Bold">Pharmacodynamics</span></a></h2>
<h2><a href="#section-11.3" class="toc"><span class="Bold">12.3</span><span class="Bold">
		     
	Pharmacokinetics </span></a></h2>
<h1><a href="#section-12" class="toc"><span class="Bold">13</span>
		     
	<span class="Bold">NONCLINICAL TOXICOLOGY</span></a></h1>
<h2><a href="#section-12.1" class="toc"><span class="Bold">13.1</span>
		     
	<span class="Bold">Carcinogenesis, Mutagenesis, Impairment of Fertility</span></a></h2>
<h2><a href="#section-12.2" class="toc"><span class="Bold">13.2</span>
		     
	<span class="Bold">Animal Toxicology and/or Pharmacology</span></a></h2>
<h1><a href="#section-13" class="toc"><span class="Bold">14</span>
		     
	<span class="Bold">CLINICAL STUDIES</span></a></h1>
<h2><a href="#section-13.1" class="toc"><span class="Bold">14.1</span>
		     
	<span class="Bold">Treatment of <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">Osteoporosis</span> in Postmenopausal Women</span></a></h2>
<h1><a href="#section-14" class="toc"><span class="Bold">16</span>
		     
	<span class="Bold">HOW SUPPLIED/STORAGE AND HANDLING</span></a></h1>
<h1><a href="#section-15" class="toc"><span class="Bold">17</span>
		     
	<span class="Bold">PATIENT COUNSELING INFORMATION</span></a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-1"></a><p></p>
<h1>
<span class="Bold">1</span><span class="Bold">
		     
	INDICATIONS AND USAGE</span>
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="_1_1_Postmenopausal_Osteoporosis"></a><a name="section-1.1"></a><p></p>
<h2>
<span class="Bold">1.1</span><span class="Bold">
		     
	Postmenopausal <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">Osteoporosis</span></span>
</h2>
<p class="First">Risedronate sodium is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> in postmenopausal women. In postmenopausal women, risedronate sodium has been shown to reduce the incidence of <span class="product-label-link" type="condition" conceptid="4066995" conceptname="Fracture of vertebral column with spinal cord injury">vertebral fractures</span> and a composite endpoint of nonvertebral <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>-related <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> [<span class="Italics"><a href="#_14_1_Treatment_of">see Clinical Studies (14.1)</a></span>]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_1_2__Important"></a><a name="section-1.2"></a><p></p>
<h2>
<span class="Bold">1.2 </span><span class="Bold">
		     
	Important Limitations of Use</span>
</h2>
<p class="First">The optimal duration of use has not been determined. The safety and effectiveness of Risedronate sodium for the treatment of <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> are based on clinical data of one year duration. All patients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis. Patients at low-risk for <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> should be considered for drug discontinuation after 3 to 5 years of use. Patients who discontinue therapy should have their risk for <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> re-evaluated periodically.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="_2_DOSAGE_AND"></a><a name="section-2"></a><p></p>
<h1>
<span class="Bold">2</span><span class="Bold">
		     
	DOSAGE AND ADMINISTRATION</span>
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="_2_1_Treatment_of"></a><a name="section-2.1"></a><p></p>
<h2>
<span class="Bold">2.1</span><span class="Bold">
		     
	Treatment</span><span class="Bold"> of Postmenopausal <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">Osteoporosis</span></span>
</h2>
<p class="First">[<span class="Italics"><a href="#_1_1_Postmenopausal_Osteoporosis">see Indications and Usage (1.1)</a></span>]</p>
<p>The recommended regimen is: </p>
<ul class="Disc"><li>one 35 mg delayed-release tablet orally, taken once-a-week</li></ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_2_2_Important_Administration"></a><a name="section-2.2"></a><p></p>
<h2>
<span class="Bold">2.</span><span class="Bold">2</span>
		     
	<span class="Bold">Important Administration Instructions</span>
</h2>
<p class="First">Instruct patients to do the following:</p>
<ul class="Disc">
<li>Take Risedronate sodium in the morning <span class="Italics Underline">immediately following</span> breakfast. Risedronate sodium should be taken immediately following breakfast and not under fasting conditions because of a higher risk of <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> if taken before breakfast when fasting.<br>
</li>
<li>Swallow Risedronate sodium whole while in an upright position and with at least 4 ounces of plain water to facilitate delivery to the stomach. Avoid lying down for 30 minutes after taking the medication [<span class="Italics">see</span> <span class="Italics"><a href="#_5_2__Upper">Warnings and Precautions (5.2)</a></span>].<br>
</li>
<li>Do not chew, cut, or crush Risedronate sodium tablets.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_2_3__Recommendations"></a><a name="section-2.3"></a><p></p>
<h2>
<span class="Bold">2.3 </span>
		     
	<span class="Bold">Recommendations for Calcium and Vitamin D Supplementation</span>
</h2>
<p class="First">Instruct patients to take supplemental calcium and vitamin D if dietary intake is inadequate [<span class="Italics"><a href="#_5_3_Mineral_Metabolism">see Warnings and Precautions (5.3)</a></span>] and to take calcium supplements, antacids, magnesium-based supplements or laxatives, and iron preparations at a different time of the day as they interfere with the absorption of Risedronate sodium. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.4"></a><p></p>
<h2>
<span class="Bold">2.4 </span><span class="Bold"> Administration Instructions for Missed Doses </span>
</h2>
<p class="First">If the once-weekly dose is missed, instruct patients to take one tablet on the morning after they remember and return to taking one tablet once-a-week, as originally scheduled on their chosen day. Patients should not take two tablets on the same day.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="_3_DOSAGE_FORMS"></a><a name="section-3"></a><p></p>
<h1>
<span class="Bold">3</span><span class="Bold">
		     
	DOSAGE FORMS AND STRENGTHS</span>
</h1>
<p class="First">Delayed-release tablets: 35 mg, yellow, oval-shaped, and engraved with EC 35 on one side.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="_4_CONTRAINDICATIONS"></a><a name="section-4"></a><p></p>
<h1>
<span class="Bold">4</span>
		     
	<span class="Bold">CONTRAINDICATIONS</span>
</h1>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Risedronate sodium is contraindicated in patients with the following conditions:</span></p>
<ul class="Disc">
<li>Abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia [<span class="Italics"><a href="#_5_2__Upper">see Warnings and Precautions (5.2)</a></span>] <br>
</li>
<li>Inability to stand or sit upright for at least 30 minutes [<span class="Italics"><a href="#_2_DOSAGE_AND">see Dosage and Administration (2)</a></span><span class="Italics">, </span><span class="Italics"><a href="#_5_2__Upper">Warnings and Precautions (5.2)</a></span>]<br>
</li>
<li><span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span> [<span class="Italics"><a href="#_5_3_Mineral_Metabolism">see Warnings and Precautions (5.3)</a></span>]<br>
</li>
<li>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any component of this product. <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span>, generalized <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, bullous <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span> and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> have been reported [<span class="Italics"><a href="#_6_2_Postmarketing_Experience">see Adverse Reactions (6.2)</a></span>]</li>
</ul>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="section-5"></a><p></p>
<h1>
<span class="Bold">5</span>
		     
	<span class="Bold">WARNINGS AND PRECAUTIONS</span>
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="_5_1_Drug_Products"></a><a name="section-5.1"></a><p></p>
<h2>
<span class="Bold">5.1</span>
		     
	<span class="Bold">Drug Products with the Same Active Ingredient</span>
</h2>
<p class="First">Risedronate sodium contains the same active ingredient found in Actonel<span class="Sup">®</span>. A patient being treated with Actonel should not receive Risedronate sodium.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_5_2__Upper"></a><a name="section-5.2"></a><p></p>
<h2>
<span class="Bold">5.</span><span class="Bold">2 </span>
		     
	<span class="Bold">Upper Gastrointestinal </span><span class="Bold">Adverse Reactions</span>
</h2>
<p class="First">Risedronate sodium, like other bisphosphonates administered orally, may cause local irritation of the upper gastrointestinal mucosa. Because of these possible irritant effects and a potential for worsening of the underlying disease, caution should be used when Risedronate sodium is given to patients with active upper gastrointestinal problems (such as known Barrett’s esophagus, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, other esophageal diseases, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="433516" conceptname="Duodenitis">duodenitis</span> or <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span>) [<span class="Italics"><a href="#_4_CONTRAINDICATIONS">see Contraindications (4)</a></span><span class="Italics">, </span><span class="Italics"><a href="#_6_1_Clinical_Studies">Adverse Reactions (6.1)</a></span><span class="Italics">, </span><span class="Italics"><a href="#_17_PATIENT_COUNSELING">Information for Patients (17)</a></span>]. </p>
<p>Esophageal adverse experiences, such as <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>, <span class="product-label-link" type="condition" conceptid="25844" conceptname="Ulcer of esophagus">esophageal ulcers</span> and <span class="product-label-link" type="condition" conceptid="4024833" conceptname="Esophageal erosions">esophageal erosions</span>, occasionally with <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and rarely followed by <span class="product-label-link" type="condition" conceptid="4268622" conceptname="Stricture of esophagus">esophageal stricture</span> or perforation, have been reported in patients receiving treatment with oral bisphosphonates. In some cases, these have been severe and required hospitalization. Physicians should therefore be alert to any signs or symptoms signaling a possible esophageal reaction and patients should be instructed to discontinue Risedronate sodium and seek medical attention if they develop <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="4147218" conceptname="Swallowing painful">odynophagia</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">retrosternal pain</span> or new or worsening <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span>. </p>
<p>The risk of severe esophageal adverse experiences appears to be greater in patients who lie down after taking oral bisphosphonates and/or who fail to swallow it with the recommended 4 ounces of water, and/or who continue to take oral bisphosphonates after developing symptoms suggestive of esophageal irritation. Therefore, it is very important that the full dosing instructions are provided to, and understood by, the patient [<span class="Italics"><a href="#_2_DOSAGE_AND">see Dosage and Administration (2)</a></span>]. In patients who cannot comply with dosing instructions due to <span class="product-label-link" type="condition" conceptid="4170893" conceptname="Mental handicap">mental disability</span>, therapy with Risedronate sodium should be used under appropriate supervision. </p>
<p>There have been post-marketing reports of gastric and <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcers</span> with oral bisphosphonate use, some severe and with complications, although no increased risk was observed in controlled clinical trials. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_5_3_Mineral_Metabolism"></a><a name="section-5.3"></a><p></p>
<h2>
<span class="Bold">5.</span><span class="Bold">3</span>
		     
	<span class="Bold">Mineral Metabolism</span>
</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span> has been reported in patients taking Risedronate sodium. Treat hypocalcemia and other disturbances of bone and mineral metabolism should be effectively treated before starting Risedronate sodium therapy. Instruct patients to take supplemental calcium and vitamin D if their dietary intake is inadequate. Adequate intake of calcium and vitamin D is important in all patients [<span class="Italics"><a href="#_4_CONTRAINDICATIONS">see Contraindications (4)</a></span><span class="Italics">, </span><span class="Italics"><a href="#_6_1_Clinical_Studies">Adverse Reactions (6.1)</a></span><span class="Italics">, </span><span class="Italics"><a href="#_17_PATIENT_COUNSELING">Information for Patients (17)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_5_4_Jaw_Osteonecrosis"></a><a name="section-5.4"></a><p></p>
<h2>
<span class="Bold">5.</span><span class="Bold">4</span>
		     
	<span class="Bold">J</span><span class="Bold">aw</span><span class="Bold"> <span class="product-label-link" type="condition" conceptid="77650" conceptname="Aseptic necrosis of bone">Osteonecrosis</span></span>
</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"><span class="product-label-link" type="condition" conceptid="77650" conceptname="Aseptic necrosis of bone">Osteonecrosis</span> of the jaw (ONJ), which can occur spontaneously, is generally associated with tooth extraction and/or local <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> with delayed healing, and has been reported in patients taking bisphosphonates, including risedronate. Known risk factors for <span class="product-label-link" type="condition" conceptid="77650" conceptname="Aseptic necrosis of bone">osteonecrosis</span> of the jaw include invasive dental procedures (for example, tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (for example, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (for example, periodontal and/or other pre-existing dental disease, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">coagulopathy</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, ill-fitting dentures). The risk of ONJ may increase with duration of exposure to bisphosphonates.</span></p>
<p>For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ. Clinical judgment of the treating physician and/or oral surgeon should guide the management plan of each patient based on individual benefit/risk assessment.</p>
<p>Patients who develop ONJ while on bisphosphonate therapy should receive care by an oral surgeon. In these patients, extensive dental surgery to treat ONJ may exacerbate the condition. Discontinuation of bisphosphonate therapy should be considered based on individual benefit/risk assessment [<span class="Italics"><a href="#_6_2_Postmarketing_Experience">see Adverse Reactions (6.2)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_5_5_Musculoskeletal_Pain"></a><a name="section-5.5"></a><p></p>
<h2>
<span class="Bold">5.</span><span class="Bold">5</span>
		     
	<span class="Bold"><span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">Musculoskeletal Pain</span></span>
</h2>
<p class="First">In postmarketing experience, there have been reports of severe and occasionally incapacitating bone, joint, and/or <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span> in patients taking bisphosphonates [<span class="Italics"><a href="#_6_2_Postmarketing_Experience">see Adverse Reactions (6.2)</a></span>]. The time to onset of symptoms varied from one day to several months after starting the drug. Most patients had relief of symptoms after stopping medication. A subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate. Consider discontinuing use if severe symptoms develop.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_5_6__Atypical"></a><a name="section-5.6"></a><p></p>
<h2>
<span class="Bold">5.6 </span><span class="Bold">
		     
	Atypical Subtrochanteric and Diaphyseal Femoral <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fractures</span></span>
</h2>
<p class="First">Atypical, low-energy, or low <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span> <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> of the femoral shaft have been reported in bisphosphonate-treated patients. These <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> can occur anywhere in the femoral shaft from just below the lesser trochanter to above the supracondylar flare and are traverse or short oblique in orientation without evidence of comminution. Causality has not been established as these <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> also occur in osteoporotic patients who have not been treated with bisphosphonates.</p>
<p>Atypical <span class="product-label-link" type="condition" conceptid="442560" conceptname="Fracture of femur">femur fractures</span> most commonly occur with minimal or no trauma to the affected area. They may be bilateral and many patients report prodromal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the affected area, usually presenting as dull, aching thigh <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, weeks to months before a complete <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> occurs. A number of reports note that patients were also receiving treatment with glucocorticoids (for example, prednisone) at the time of <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span>.</p>
<p>Any patient with a history of bisphosphonate exposure who presents with thigh or <span class="product-label-link" type="condition" conceptid="4010361" conceptname="Inguinal pain">groin pain</span> should be suspected of having an atypical <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> and should be evaluated to rule out an incomplete <span class="product-label-link" type="condition" conceptid="442560" conceptname="Fracture of femur">femur fracture</span>. Patients presenting with an atypical <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> should also be assessed for symptoms and signs of <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> in the contralateral limb. Interruption of bisphosphonate therapy should be considered, pending a risk/benefit assessment, on an individual basis.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_5_6_Renal_Impairment"></a><a name="section-5.7"></a><p></p>
<h2>
<span class="Bold">5.</span><span class="Bold">7</span>
		     
	<span class="Bold">Renal I</span><span class="Bold">mpairment</span>
</h2>
<p class="First">Risedronate sodium is not recommended for use in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance less than 30 mL/min) because of lack of clinical experience.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.8"></a><p></p>
<h2>
<span class="Bold">5.</span><span class="Bold">8</span><span class="Bold">
		     
	Laboratory Test Interactions</span>
</h2>
<p class="First">Bisphosphonates are known to interfere with the use of bone-imaging agents. Specific studies with Risedronate sodium have not been performed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-6"></a><p></p>
<h1>
<span class="Bold">6</span>
		     
	<span class="Bold">ADVERSE REACTIONS</span>
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="_6_1_Clinical_Studies"></a><a name="section-6.1"></a><p></p>
<h2>
<span class="Bold">6.1</span>
		     
	<span class="Bold">Clinical Studies Experience</span>
</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p><span class="Bold">Treatment of Postmenopausal <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">Osteoporosis</span></span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1"></a><p></p>
<h3>
<span class="Underline">Once-a-Week Dosing with </span><span class="Underline">Risedronate sodium</span><span class="Underline"> </span><span class="Underline">(</span><span class="Underline">risedronate sodium) </span><span class="Underline">delayed-release </span><span class="Underline">tablets</span>
</h3>
<p class="First">The safety of Risedronate sodium 35 mg once-a-week in the treatment of postmenopausal <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> was assessed in a 1-year, double-blind, multicenter study comparing Risedronate sodium 35 mg once-a-week to risedronate sodium immediate-release 5 mg daily in postmenopausal women 50 years of age or older. Risedronate sodium was administered either at least 30 minutes before (N = 308) or immediately following (N = 307) breakfast, and risedronate sodium immediate-release 5 mg daily (N = 307) was administered at least 30 minutes before breakfast. Patients with pre-existing gastrointestinal disease and concomitant use of non-steroidal anti-inflammatory drugs, proton pump inhibitors, and H<span class="Sub">2</span> antagonists were included in this clinical trial. All women received daily supplementation with 1000 mg of elemental calcium plus 800 to 1000 international units vitamin D. As treatment with Risedronate sodium resulted in a significantly higher incidence of <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> when administered before breakfast under fasting conditions, safety results that follow refer only to Risedronate sodium 35 mg once-a-week immediately following breakfast and risedronate sodium immediate-release 5 mg daily.</p>
<p>The incidence of all-cause mortality was 0.0% in the Risedronate sodium 35 mg once-a-week group and 0.3% in the risedronate sodium immediate-release 5 mg daily group. The incidence of serious adverse reactions was 6.5% in the Risedronate sodium 35 mg once-a-week group and 7.2% in the risedronate sodium immediate-release 5 mg daily group. The percentage of patients who withdrew from the study due to adverse reactions was 9.1% in the Risedronate sodium 35 mg once-a-week group and 8.1% in the risedronate sodium immediate-release 5 mg daily group. The overall safety and tolerability profiles of the two dosing regimens were similar. Table 1 lists adverse reactions reported in greater than or equal to 2% of patients. Adverse reactions are shown without attribution of causality.</p>
<table>
<caption><span>Table 1 Adverse Reactions Occurring at a Frequency of greater than or equal to 2% in Either Treatment Group</span></caption>
<col width="330">
<col width="96">
<col width="102">
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule" align="center"></td>
<td class="Lrule Rrule" align="center">
<span class="Bold">35 mg</span><br><span class="Bold">Risedronate sodium </span><br><span class="Bold">Delayed-release</span>
</td>
<td class="Lrule Rrule" align="center">
<span class="Bold">5 mg</span><br><span class="Bold">Risedronate sodium </span><br><span class="Bold">I</span><span class="Bold">mmediate</span><span class="Bold">-</span><span class="Bold"> release </span>
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center"></td>
<td class="Lrule Rrule" align="center"><span class="Bold">Weekly</span></td>
<td class="Lrule Rrule" align="center"><span class="Bold">Daily</span></td>
</tr>
<tr>
<td class="Lrule Rrule"><span class="Bold">System Organ Class</span></td>
<td class="Lrule Rrule" align="center">
<span class="Bold">N</span><span class="Bold"> </span><span class="Bold">=</span><span class="Bold"> </span><span class="Bold">307</span>
</td>
<td class="Lrule Rrule" align="center">
<span class="Bold">N</span><span class="Bold"> </span><span class="Bold">=</span><span class="Bold"> </span><span class="Bold">307</span>
</td>
</tr>
<tr>
<td class="Lrule Rrule"><span class="Bold">   Preferred Term</span></td>
<td class="Lrule Rrule" align="center">
<span class="Bold"> </span><span class="Bold">%</span>
</td>
<td class="Lrule Rrule" align="center">
<span class="Bold"> </span><span class="Bold">%</span>
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule">  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Lrule Rrule" align="center">8.8</td>
<td class="Lrule Rrule" align="center">4.9</td>
</tr>
<tr>
<td class="Lrule Rrule">  <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></td>
<td class="Lrule Rrule" align="center">5.2</td>
<td class="Lrule Rrule" align="center">2.9</td>
</tr>
<tr>
<td class="Lrule Rrule">  <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td class="Lrule Rrule" align="center">4.9</td>
<td class="Lrule Rrule" align="center">2.9</td>
</tr>
<tr>
<td class="Lrule Rrule">  <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Lrule Rrule" align="center">4.9</td>
<td class="Lrule Rrule" align="center">1.6</td>
</tr>
<tr>
<td class="Lrule Rrule">  <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td class="Lrule Rrule" align="center">3.9</td>
<td class="Lrule Rrule" align="center">3.9</td>
</tr>
<tr>
<td class="Lrule Rrule">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Lrule Rrule" align="center">3.6</td>
<td class="Lrule Rrule" align="center">3.9</td>
</tr>
<tr>
<td class="Lrule Rrule">  <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">Abdominal pain upper</span></td>
<td class="Lrule Rrule" align="center">2.9</td>
<td class="Lrule Rrule" align="center">2.3</td>
</tr>
<tr>
<td class="Lrule Rrule"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestations</span></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule">  <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Influenza</span></td>
<td class="Lrule Rrule" align="center">7.2</td>
<td class="Lrule Rrule" align="center">6.2</td>
</tr>
<tr>
<td class="Lrule Rrule">  <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">Bronchitis</span></td>
<td class="Lrule Rrule" align="center">3.9</td>
<td class="Lrule Rrule" align="center">4.2</td>
</tr>
<tr>
<td class="Lrule Rrule">  <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infection</span></td>
<td class="Lrule Rrule" align="center">3.6</td>
<td class="Lrule Rrule" align="center">2.6</td>
</tr>
<tr>
<td class="Lrule Rrule">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">connective tissue disorders</span></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule">  <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></td>
<td class="Lrule Rrule" align="center">6.8</td>
<td class="Lrule Rrule" align="center">7.8</td>
</tr>
<tr>
<td class="Lrule Rrule">  <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span></td>
<td class="Lrule Rrule" align="center">6.8</td>
<td class="Lrule Rrule" align="center">5.9</td>
</tr>
<tr>
<td class="Lrule Rrule">  <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">Pain in extremity</span></td>
<td class="Lrule Rrule" align="center">3.9</td>
<td class="Lrule Rrule" align="center">2.3</td>
</tr>
<tr>
<td class="Lrule Rrule">  <span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">Musculoskeletal pain</span></td>
<td class="Lrule Rrule" align="center">2.0</td>
<td class="Lrule Rrule" align="center">1.6</td>
</tr>
<tr>
<td class="Lrule Rrule">  <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Muscle spasms</span></td>
<td class="Lrule Rrule" align="center">1.0</td>
<td class="Lrule Rrule" align="center">2.3</td>
</tr>
<tr>
<td class="Lrule Rrule"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span></td>
<td class="Lrule Rrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule">  <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Lrule Rrule" align="center">2.6</td>
<td class="Lrule Rrule" align="center">3.3</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule">  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Lrule Rrule" align="center">2.6</td>
<td class="Lrule Rrule" align="center">4.9</td>
</tr>
</tbody>
</table>
<p><span class="Italics">Acute Phase Reactions: </span>Symptoms consistent with acute phase reaction have been reported with bisphosphonate use. The overall incidence of acute phase reaction was 2.3% in the Risedronate sodium 35 mg once-a-week group and 1.3% in the risedronate sodium immediate-release 5 mg daily group. These incidence rates are based on reporting of one or more pre-specified acute phase reaction-like symptoms within 3 days of the first dose and for a duration of 7 days or less. </p>
<p><span class="Italics">Gastrointestinal Adverse </span><span class="Italics">Reactions</span>: Adverse reactions related to the upper gastrointestinal tract occurred in 16% of subjects treated with Risedronate sodium 35 mg once-a-week and 15% of subjects treated with risedronate sodium immediate-release 5 mg daily. The incidence of upper gastrointestinal tract adverse reactions in the Risedronate sodium 35 mg once-a-week and risedronate sodium immediate-release 5 mg daily groups were: <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (5.2% versus 2.9%), <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span> (3.9% versus 3.9%), <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">upper abdominal pain</span> (2.9% versus 2.3%), <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span> (1.0% versus 1.0%), and <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">gastroesophageal reflux disease</span> (1.0% versus 1.6%). Study discontinuation due to <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> occurred in 1.3% of the Risedronate sodium 35 mg once-a-week group and 0.7% of the risedronate sodium immediate-release 5 mg daily group.</p>
<p><span class="Italics">Musculoskeletal Adverse </span><span class="Italics">Reactions</span><span class="Italics">:</span> Selected musculoskeletal adverse reactions were reported in 16% of subjects treated with Risedronate sodium 35 mg once-a-week and 15% of subjects treated with risedronate sodium immediate-release 5 mg daily. The incidence of musculoskeletal adverse reactions in the Risedronate sodium 35 mg once-a-week and risedronate sodium immediate-release 5 mg daily groups were: <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span> (6.8% versus 7.8%), <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span> (6.8% versus 5.9%), <span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">musculoskeletal pain</span> (2.0% versus 1.6%), and <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span> (1.3% versus 1.0%). </p>
<p><span class="Italics">Laboratory Test Findings</span>:  </p>
<p><span class="Underline">Parathyroid hormone</span>: The effect of Risedronate sodium 35 mg once-a-week and risedronate sodium immediate-release 5 mg daily on parathyroid hormone was evaluated  in postmenopausal women with <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>. At week 52, in subjects with normal levels at baseline, PTH levels greater than 65 pg/mL (upper limit of normal) were noted in 9% of subjects receiving Risedronate sodium 35 mg once-a-week and 8% of subjects receiving risedronate sodium immediate-release 5 mg daily. In subjects with normal levels at baseline, PTH levels greater than 97 pg/mL (1.5 times the upper limit of normal) were seen in 2% of subjects receiving Risedronate sodium 35 mg once-a-week and no subjects receiving risedronate sodium immediate-release 5 mg daily. There were no clinically significant differences between treatment groups for levels of calcium, phosphorus and magnesium.</p>
<p><span class="Underline">Daily Dosing </span><span class="Underline">with</span><span class="Underline"> </span><span class="Underline">risedronate sodium </span><span class="Underline">immediate</span><span class="Underline">-</span><span class="Underline">release </span><span class="Underline">5 mg </span><span class="Underline">tablets</span></p>
<p>The safety of risedronate sodium immediate-release 5 mg once daily in the treatment of postmenopausal <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> was assessed in four randomized, double-blind, placebo-controlled multinational trials of 3232 women aged 38 to 85 years with postmenopausal <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>. The duration of the trials was up to three years, with 1619 patients exposed to placebo and 1613 patients exposed to risedronate sodium immediate-release 5 mg daily. Patients with pre-existing gastrointestinal disease and concomitant use of non-steroidal anti-inflammatory drugs, proton pump inhibitors (PPIs), and H<span class="Sub">2</span> antagonists were included in these clinical trials. All women received 1000 mg of elemental calcium plus vitamin D supplementation up to 500 international units per day if their 25-hydroxyvitamin D<span class="Sub">3</span> level was below normal at baseline. </p>
<p>The incidence of all-cause mortality was 2.0% in the placebo group and 1.7% in the risedronate sodium immediate-release 5 mg daily group. The incidence of serious adverse reactions was 24.6% in the placebo group and 27.2% in the risedronate sodium immediate-release 5 mg daily group. The percentage of patients who withdrew from the study due to adverse reactions was 15.6% in the placebo group and 14.8% in the risedronate sodium immediate-release 5 mg daily group. The most common adverse reactions reported in greater than 10% of subjects were: <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> and <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>. </p>
<p><span class="Italics">Gastrointestinal Adverse </span><span class="Italics">Reactions</span><span class="Italics">:</span> The incidence of adverse reactions in the placebo and risedronate sodium immediate-release 5 mg daily groups were: <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (9.9% versus 12.2%), <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (10.0% versus 10.8%), <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span> (10.6% versus 10.8%), and <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span> (2.3% versus 2.7%). <span class="product-label-link" type="condition" conceptid="433516" conceptname="Duodenitis">Duodenitis</span> and <span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">glossitis</span> have been reported uncommonly in the risedronate sodium immediate-release 5 mg daily group (0.1% to 1%). In patients with active upper gastrointestinal disease at baseline, the incidence of upper gastrointestinal adverse reactions was similar between the placebo and risedronate sodium immediate-release 5 mg daily groups.</p>
<p><span class="Italics">Musculoskeletal Adverse </span><span class="Italics">Reactions</span><span class="Italics">:</span> The incidence of adverse reactions in the placebo and risedronate sodium immediate-release 5 mg daily groups were: <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span> (26.1% versus 28.0%), <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span> (22.1% versus 23.7%), <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span> (6.2% versus 6.7%), and <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">bone pain</span> (4.8% versus 5.3%).</p>
<p><span class="Italics">Laboratory Test Findings</span>: Throughout the Phase 3 studies, transient decreases from baseline in serum calcium (less than 1%) and serum phosphate (less than 3%) and compensatory increases in serum PTH levels (less than 30%) were observed within 6 months in patients in <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> clinical trials treated with risedronate sodium immediate-release 5 mg daily. There were no significant differences in serum calcium, phosphate, or PTH levels between placebo and risedronate sodium immediate-release 5 mg daily at 3 years. Serum calcium levels below 8 mg/dL were observed in 18 patients, 9 (0.5%) in each treatment arm (placebo and risedronate sodium immediate-release 5 mg daily). Serum phosphorus levels below 2 mg/dL were observed in 14 patients, 3 (0.2%) treated with placebo and 11 (0.6%) treated with risedronate sodium immediate-release 5 mg daily. There have been rare reports (less than 0.1%) of <span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">abnormal liver function tests</span>.</p>
<p><span class="Italics">Endoscopic Findings</span>: In the risedronate sodium immediate-release 5 mg daily clinical trials, endoscopic evaluation was encouraged in any patient with moderate-to-severe gastrointestinal complaints, while maintaining the blind. Endoscopies were performed on equal numbers of patients between the placebo and treated groups [75 (14.5%) placebo; 75 (11.9%) risedronate sodium immediate-release 5 mg daily]. Clinically important findings (perforations, <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span>, or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>) among this symptomatic population were similar between groups (51% placebo; 39% risedronate sodium immediate-release 5 mg daily).</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_6_2_Postmarketing_Experience"></a><a name="section-6.2"></a><p></p>
<h2>
<span class="Bold">6.</span><span class="Bold">2</span><span class="Bold">
		     
	Postmarketing Experience</span>
</h2>
<p class="First">The following adverse reactions have been reported with the use of Risedronate sodium. Because these adverse reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> and <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> have been reported, including <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, generalized <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>,  bullous <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span> and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>. </p>
<p><span class="Underline">Gastrointestinal </span><span class="Underline">Adverse </span><span class="Underline">Reactions</span></p>
<p>Reactions involving upper <span class="product-label-link" type="condition" conceptid="4318531" conceptname="Gastrointestinal irritation">gastrointestinal irritation</span>, such as <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span> and esophageal or <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">gastric ulcers</span>, have been reported [<span class="Italics"><a href="#_5_2__Upper">see Warnings and Precautions (5.2)</a></span>].</p>
<p><span class="Underline">Musculoskeletal</span><span class="Underline"> <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></span></p>
<p>Bone, joint, or <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>, described as severe or incapacitating, have been reported rarely [<span class="Italics"><a href="#_5_5_Musculoskeletal_Pain">see Warnings and Precautions (5.5)</a></span>].  </p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="376709" conceptname="Discharge of eye">Eye Inflammation</span></span></p>
<p>Reactions of <span class="product-label-link" type="condition" conceptid="376709" conceptname="Discharge of eye">eye inflammation</span> including <span class="product-label-link" type="condition" conceptid="4274964" conceptname="Iritis">iritis</span> and <span class="product-label-link" type="condition" conceptid="4028363" conceptname="Uveitis">uveitis</span> have been reported rarely.</p>
<p><span class="Underline">Jaw </span><span class="Underline"><span class="product-label-link" type="condition" conceptid="77650" conceptname="Aseptic necrosis of bone">Osteonecrosis</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="77650" conceptname="Aseptic necrosis of bone">Osteonecrosis</span> of the jaw has been reported rarely [<span class="Italics"><a href="#_5_4_Jaw_Osteonecrosis">see Warnings and Precautions (5.4)</a></span>].</p>
<p><span class="Underline">Pulmonary</span></p>
<p><span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span> exacerbations</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="_7_DRUG_INTERACTIONS"></a><a name="section-7"></a><p></p>
<h1>
<span class="Bold">7</span>
		     
	<span class="Bold">DRUG INTERACTIONS</span>
</h1>
<p class="First">Risedronate is not metabolized and does not induce or inhibit hepatic microsomal drug-metabolizing enzymes (for example, Cytochrome P450).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="_7_1_Calcium_Supplements_Antacids"></a><a name="section-7.1"></a><p></p>
<h2>
<span class="Bold">7.1</span>
		     
	<span class="Bold">Calcium Supplements/Antacids</span>
</h2>
<p class="First">When Risedronate sodium  was administered following breakfast, the co-administration of a tablet containing 600 mg of elemental calcium and 400 international units vitamin D reduced risedronate bioavailability by approximately 38% [<span class="Italics"><a href="#_12_3_Pharmacokinetics">see Clinical Pharmacology (12.3)</a></span>]. Calcium supplements, antacids, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of Risedronate sodium and should not be taken together.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2"></a><p></p>
<h2>
<span class="Bold">7.2</span><span class="Bold">
		     
	Histamine 2 (H</span><span class="Bold"><span class="Sub">2</span></span><span class="Bold">) Blockers and Proton Pump Inhibitors (PPIs)</span>
</h2>
<p class="First">Drugs that raise stomach pH (for example, PPIs or H<span class="Sub">2</span> blockers) may cause faster drug release from enteric coated (delayed-release) drug products such as Risedronate sodium. Co-administration of Risedronate sodium with the PPI, esomeprazole, increased risedronate bioavailability. The maximum plasma concentration (C<span class="Sub">max</span>) and the area under the plasma concentration (AUC) were increased by 60 percent and 22 percent, respectively.</p>
<p>Concomitant administration of Risedronate sodium and H<span class="Sub">2</span> blockers or PPIs is not recommended.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3"></a><p></p>
<h2>
<span class="Bold">7.</span><span class="Bold">3</span>
		     
	<span class="Bold">Hormone Therapy</span>
</h2>
<p class="First">Concomitant use of Risedronate sodium with estrogens and estrogen agonist/antagonists has not been studied.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.4"></a><p></p>
<h2>
<span class="Bold">7.</span><span class="Bold">4</span><span class="Bold"> </span><span class="Bold">
		     
	Aspirin/Nonsteroidal Anti-Inflammatory Drugs</span>
</h2>
<p class="First">In the Phase 3 study comparing Risedronate sodium  35 mg once-a-week immediately following breakfast and risedronate sodium 5 mg daily, 18% of NSAID users (any use) in both groups developed upper gastrointestinal adverse reactions. Among non-users, 13% of patients taking Risedronate sodium 35 mg once-a-week immediately following breakfast developed upper gastrointestinal adverse reactions, compared to 12% taking risedronate sodium 5 mg daily.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="section-8"></a><p></p>
<h1>
<span class="Bold">8</span>
		     
	<span class="Bold">USE IN SPECIFIC POPULATIONS</span>
</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="section-8.1"></a><p></p>
<h2>
<span class="Bold">8.1</span>
		     
	<span class="Bold">Pregnancy</span>
</h2>
<p class="First">Pregnancy Category C: There are no adequate and well-controlled studies of Risedronate sodium in pregnant women. Risedronate sodium should be used during pregnancy only if the potential benefit justifies the potential risk to the mother and fetus.</p>
<p>Bisphosphonates are incorporated into the bone matrix, from which they are gradually released over periods of weeks to years. The amount of bisphosphonate incorporation into adult bone, and hence, the amount available for release back into the systemic circulation, is directly related to the dose and duration of bisphosphonate use. There are no data on fetal risk in humans. However, there is a theoretical risk of fetal harm, predominantly skeletal, if a woman becomes pregnant after completing a course of bisphosphonate therapy. The impact of variables such as time between cessation of bisphosphonate therapy to conception, the particular bisphosphonate used, and the route of administration (intravenous versus oral) on this risk has not been studied. </p>
<p>In animal studies, pregnant rats received risedronate sodium during organogenesis at doses 1 to 26 times the human Paget’s disease dose of 30 mg/day. Survival of neonates was decreased in rats treated during gestation with oral doses approximately 5 times the human dose and body weight was decreased in neonates from dams treated with approximately 26 times the human dose. The number of fetuses exhibiting incomplete ossification of sternebrae or skull from dams treated with approximately 2.5 times the human dose was significantly increased compared to controls. Both incomplete ossification and unossified sternebrae were increased in rats treated with oral doses approximately 5 times the human dose. A low incidence of <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span> was observed in fetuses from female rats treated with oral doses approximately equal to the human dose. The relevance of this finding to human use of Risedronate sodium is unclear. </p>
<p>No significant fetal ossification effects were seen in rabbits treated with oral doses approximately 7 times the human dose (the highest dose tested). However, 1 of 14 litters were aborted and 1 of 14 litters were delivered prematurely.</p>
<p>Similar to other bisphosphonates, treatment during mating and gestation with doses of risedronate sodium approximately the same as the human Paget’s disease dose of 30 mg/day resulted in periparturient <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span> and mortality in pregnant rats allowed to deliver.</p>
<p>Dosing multiples provided above are based on the recommended human Paget’s disease dose of 30 mg/day and normalized using body surface area (mg/m<span class="Sup">2</span>). Actual animal doses were 3.2, 7.1 and 16 mg/kg/day in the rat and 10 mg/kg/day in the rabbit.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-8.2"></a><p></p>
<h2>
<span class="Bold">8.3</span>
		     
	<span class="Bold">Nursing </span><span class="Bold">Mothers</span>
</h2>
<p class="First">Risedronate was detected in feeding pups exposed to lactating rats for a 24-hour period post-dosing, indicating a small degree of lacteal transfer. It is not known whether Risedronate sodium is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Risedronate sodium, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="_8_4_Pediatric_Use"></a><a name="section-8.3"></a><p></p>
<h2>
<span class="Bold">8.4</span>
		     
	<span class="Bold">Pediatric Use</span>
</h2>
<p class="First">Risedronate sodium is not indicated for use in pediatric patients.</p>
<p>The safety and effectiveness of risedronate sodium immediate-release was assessed in a one-year, randomized, double-blind, placebo-controlled study of 143 pediatric patients (94 received risedronate) with <span class="product-label-link" type="condition" conceptid="78257" conceptname="Osteogenesis imperfecta">osteogenesis imperfecta</span> (OI). The enrolled population was predominantly patients with mild OI (85% Type-I), aged 4 to less than 16 years, 50% male and 82% Caucasian, with a mean lumbar spine BMD Z-score of -2.08 (2.08 standard deviations below the mean for age-matched controls). Patients received either a 2.5 mg (less than or equal to 30 kg body weight) or 5 mg (greater than 30 kg body weight) daily oral dose. After one year, an increase in lumbar spine BMD in the risedronate sodium immediate-release group compared to the placebo group was observed. However, treatment with risedronate sodium immediate-release did not result in a reduction in the risk of <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> in pediatric patients with OI. In risedronate sodium immediate-release treated subjects, no mineralization defects were noted in paired bone biopsy specimens obtained at baseline and month 12.</p>
<p>The overall safety profile of risedronate in OI patients treated for up to 12 months was generally similar to that of adults with <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>. However, there was an increased incidence of <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> compared to placebo. In this study, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> was observed in 15% of children treated with risedronate sodium immediate-release and 6% of patients treated with placebo. Other adverse reactions reported in greater than or equal to 10% of patients treated with risedronate sodium immediate-release and with a higher frequency than placebo were: <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the extremity (21% with risedronate sodium immediate-release versus 16% with placebo), <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (20% versus 8%), <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span> (17% versus 10%), <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> (15% versus 10%), <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">upper abdominal pain</span> (11% versus 8%), and <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">bone pain</span> (10% versus 4%).</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-8.4"></a><p></p>
<h2>
<span class="Bold">8.5</span>
		     
	<span class="Bold">Geriatric Use</span>
</h2>
<p class="First">Of the patients receiving Risedronate sodium in postmenopausal <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> studies, 59% were 65 and over, while 13% were 75 and over. No overall differences in safety or effectiveness were observed between these patients and younger patients, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="_8_6_Renal_Impairment"></a><a name="section-8.5"></a><p></p>
<h2>
<span class="Bold">8.6</span><span class="Bold">
		     
	<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span>
</h2>
<p class="First">Risedronate sodium is not recommended for use in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance less than 30 mL/min) because of lack of clinical experience. No dosage adjustment is necessary in patients with a creatinine clearance greater than or equal to 30 mL/min.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.6"></a><p></p>
<h2>
<span class="Bold">8.7</span><span class="Bold">
		     
	<span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span>
</h2>
<p class="First">No studies have been performed to assess risedronate sodium’s safety or efficacy in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Risedronate is not metabolized in human liver preparations. Dosage adjustment is unlikely to be needed in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>
<span class="Bold">10</span>
		     
	<span class="Bold">OVERDOSAGE</span>
</h1>
<p class="First">Decreases in serum calcium and phosphorus following substantial <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> may be expected in some patients. Signs and symptoms of <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span> may also occur in some of these patients. While milk or antacids containing calcium may be given to bind risedronate sodium immediate- release and reduce absorption of the drug, the impact of this intervention for Risedronate sodium delayed-release tablets has not been evaluated. </p>
<p>In cases of substantial <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, gastric lavage may be considered to remove unabsorbed drug. Standard procedures that are effective for treating <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>, including the administration of calcium intravenously, would be expected to restore physiologic amounts of <span class="product-label-link" type="condition" conceptid="4125860" conceptname="Calcium electrolyte">ionized calcium</span> and to relieve signs and symptoms of <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>. </p>
<p>Lethality after single oral doses of risedronate was seen in female rats at 903 mg/kg and male rats at 1703 mg/kg. The minimum lethal dose in mice and rabbits was 4000 mg/kg and 1000 mg/kg, respectively. These values represent 320 to 620 times the human Paget’s disease dose of 30 mg/day based on surface area (mg/m<span class="Sup">2</span>). </p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-10"></a><p></p>
<h1>
<span class="Bold">11</span>
		     
	<span class="Bold">DESCRIPTION</span>
</h1>
<p class="First">Risedronate sodium delayed-release tablets contain a pH-sensitive enteric coating and a chelating agent (EDTA). </p>
<p>Risedronate is a pyridinyl bisphosphonate that inhibits osteoclast-mediated bone resorption and modulates bone metabolism. Each Risedronate sodium tablet for oral administration contains the equivalent of 35 mg of anhydrous risedronate sodium in the form of the hemi-pentahydrate with small amounts of monohydrate. The empirical formula for risedronate sodium hemi-pentahydrate is C<span class="Sub">7</span>H<span class="Sub">10</span>NO<span class="Sub">7</span>P<span class="Sub">2</span>Na •2.5 H<span class="Sub">2</span>O. The chemical name of risedronate sodium is [1-hydroxy-2-(3-pyridinyl)ethylidene]bis[phosphonic acid] monosodium salt. The chemical structure of risedronate sodium hemi-pentahydrate is the following:</p>
<p><img alt="risedronate sodium hemi-pentahydrate chemical structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ef2dbc86-b4f5-4990-a83f-0b121cfe2ec1&amp;name=risedronate-sodium-delayed-release-tablets-01.jpg"></p>
<p>
		     
	Molecular Weight:</p>
<p>
		     
	Anhydrous:
		     
	305.10</p>
<p>
		     
	Hemi-pentahydrate:
		     
	350.13</p>
<p>Risedronate sodium is a fine, white to off-white, odorless, crystalline powder. It is soluble in water and in aqueous solutions, and essentially insoluble in common organic solvents.</p>
<p><span class="Underline">Inactive Ingredients</span></p>
<p>Edetate disodium, ferric oxide yellow, magnesium stearate, methacrylic acid copolymer, polysorbate 80, silicified microcrystalline cellulose (ProSolv SMCC90), simethicone, sodium starch glycolate, stearic acid, talc, and triethyl citrate.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-11"></a><p></p>
<h1>
<span class="Bold">12</span>
		     
	<span class="Bold">CLINICAL PHARMACOLOGY</span>
</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="section-11.1"></a><p></p>
<h2>
<span class="Bold">12.1</span>
		     
	<span class="Bold">Mechanism of Action</span>
</h2>
<p class="First">Risedronate has an affinity for hydroxyapatite crystals in bone and acts as an antiresorptive agent. At the cellular level, risedronate inhibits osteoclasts. The osteoclasts adhere normally to the bone surface, but show evidence of reduced active resorption (for example, lack of ruffled border). Histomorphometry in rats, dogs, and minipigs showed that risedronate treatment reduces bone turnover (activation frequency, that is, the rate at which bone remodeling sites are activated) and bone resorption at remodeling sites.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="section-11.2"></a><p></p>
<h2>
<span class="Bold">12.2</span>
		     
	<span class="Bold">Pharmacodynamics</span>
</h2>
<p class="First">Risedronate treatment decreases the elevated rate of bone turnover that is typically seen in postmenopausal <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>. In clinical trials, administration of risedronate sodium immediate- release to postmenopausal women resulted in decreases in biochemical markers of bone turnover, including urinary deoxypyridinoline/creatinine and urinary collagen cross-linked N-telopeptide (markers of bone resorption) and serum bone-specific alkaline phosphatase (a marker of bone formation). At the 5 mg daily dose, decreases in deoxypyridinoline/creatinine were evident within 14 days of treatment. Changes in bone formation markers were observed later than changes in resorption markers, as expected, due to the coupled nature of bone resorption and bone formation; decreases in bone-specific alkaline phosphatase of about 20% were evident within 3 months of treatment. Bone turnover markers reached a nadir of about 40% below baseline values by the sixth month of treatment and remained stable with continued treatment for up to 3 years. Bone turnover is decreased as early as 14 days and maximally within about 6 months of treatment, with achievement of a new steady-state that more nearly approximates the rate of bone turnover seen in premenopausal women. In a 1-year study comparing Risedronate sodium  35 mg weekly taken immediately after breakfast versus risedronate sodium immediate-release 5 mg daily oral dosing regimens in postmenopausal women, mean decreases from baseline at 1 year in urinary collagen cross-linked N-telopeptide were 47% in the Risedronate sodium  35 mg once-a-week following breakfast group and 42% in the risedronate sodium immediate-release 5 mg daily group. In addition, serum bone-specific alkaline phosphatase at 1 year was reduced by 33% in the Risedronate sodium  35 mg once-a-week following breakfast group and 32% in the risedronate sodium immediate-release 5 mg daily group.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="_12_3_Pharmacokinetics"></a><a name="section-11.3"></a><p></p>
<h2>
<span class="Bold">12.3</span><span class="Bold">
		     
	Pharmacokinetics </span>
</h2>
<p class="First"><span class="Underline">Absorption</span></p>
<p>The mean absolute oral bioavailability of the 30 mg risedronate sodium immediate-release tablet taken 4 hours prior to a meal is 0.63% (90% confidence interval [CI]: 0.54% to 0.75%) and is similar to an oral solution. The time to peak concentration (T<span class="Sub">max</span>) for Risedronate sodium  tablet is approximately 3 hours when administered in the morning 4 hours prior to a meal. </p>
<p><span class="Italics Underline">Food Effect</span><span class="Underline"> </span></p>
<p>In a crossover pharmacokinetic study, the bioavailability of Risedronate sodium  35 mg delayed-release tablets decreased by approximately 30% when administered immediately after a high-fat breakfast compared to administration in the morning 4 hours before a meal.</p>
<p>The bioavailability of the 35 mg Risedronate sodium  tablet administered after a high-fat breakfast was similar to risedronate sodium 35 mg immediate-release tablet dosed 4 hours before a meal in one study and was approximately 2- to 4-fold greater than the immediate-release 35 mg tablet administered 30 minutes prior to a high-fat breakfast.</p>
<p>In a separate study, Risedronate sodium  administered after dinner exhibited approximately 87% increase in risedronate exposure compared to administration following a breakfast. The safety and efficacy of dosing Risedronate sodium  after dinner has not been evaluated [<span class="Italics"><a href="#_2_DOSAGE_AND">see Dosage and Administration (2)</a></span>]. </p>
<p><span class="Underline">Distribution</span></p>
<p>The mean steady-state volume of distribution for risedronate is 13.8 L/kg in humans. Human plasma protein binding of drug is about 24%. Preclinical studies in rats and dogs dosed intravenously with single doses of [<span class="Sup">14</span>C] risedronate indicate that approximately 60% of the dose is distributed to bone. The remainder of the dose is excreted in the urine. After multiple oral dosing in rats, the uptake of risedronate in soft tissues was in the range of 0.001% to 0.01%.</p>
<p><span class="Underline">Metabolism</span></p>
<p>There is no evidence of systemic metabolism of risedronate.</p>
<p><span class="Underline">Excretion</span></p>
<p>In young healthy subjects, approximately half of the absorbed dose of risedronate was excreted in urine within 24 hours, and 85% of an intravenous dose was recovered in the urine over 28 days. Based on simultaneous modeling of serum and urine data for the risedronate sodium immediate-release tablets, mean renal clearance was 105 mL/min (CV = 34%) and mean total clearance was 122 mL/min (CV = 19%), with the difference primarily reflecting nonrenal clearance or clearance due to adsorption to bone. The renal clearance is not concentration dependent, and there is a linear relationship between renal clearance and creatinine clearance. Unabsorbed drug is eliminated unchanged in feces. In osteopenic postmenopausal women, the terminal exponential half-life was 561 hours, mean renal clearance was 52 mL/min (CV = 25%), and mean total clearance was 73 mL/min (CV = 15%).</p>
<p><span class="Underline">Specific Populations</span></p>
<p><span class="Italics">Pediatric:</span> Risedronate sodium  is not indicated for use in pediatric patients [<span class="Italics"><a href="#_8_4_Pediatric_Use">see Pediatric Use (8.4)</a></span>].</p>
<p><span class="Italics">Geriatric:</span> Effect of age on bioavailability of Risedronate sodium  has not been evaluated. Based on data from risedronate immediate-release tablet, bioavailability and disposition of risedronate are similar in elderly (greater than 60 years of age) and younger subjects. No dosage adjustment is necessary.</p>
<p><span class="Italics">Race:</span> Pharmacokinetic differences due to race have not been studied. The clinical trial of Risedronate sodium was conducted mostly in Caucasians.</p>
<p><span class="Italics">Renal </span><span class="Italics">Impairment</span><span class="Italics">:</span> Risedronate is excreted unchanged primarily via the kidney. As compared to persons with normal renal function, the renal clearance of risedronate was decreased by about 70% in patients with creatinine clearance of approximately 30 mL/min. Risedronate sodium is not recommended for use in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance less than 30 mL/min). No dosage adjustment is necessary in patients with a creatinine clearance greater than or equal to 30 mL/min.</p>
<p><span class="Italics">Hepatic </span><span class="Italics">Impairment</span><span class="Italics">:</span> No studies have been performed to assess risedronate’s safety or efficacy in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Risedronate is not metabolized in rat, dog, and human liver preparations. Insignificant amounts (less than 0.1% of intravenous dose) of drug are excreted in the bile in rats. Therefore, dosage adjustment is unlikely to be needed in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. </p>
<p><span class="Italics">Drug Interactions: </span>Risedronate is not metabolized and does not induce or inhibit hepatic microsomal drug-metabolizing enzymes (for example, Cytochrome P450). </p>
<p><span class="Italics">Calcium supplement:</span><span class="Italics"> </span>A Phase 1 single-dose, cross-over study in 101 postmenopausal women evaluated the relative bioavailability of Risedronate sodium  35 mg delayed-release tablets taken after breakfast and following a 600 mg elemental calcium/400 international units vitamin D supplement, compared to Risedronate sodium  alone taken after breakfast without calcium or vitamin D supplementation. The addition of the calcium/vitamin D supplement following the meal resulted in an approximate 38% reduction in the amount of risedronate absorbed [<span class="Italics"><a href="#_7_DRUG_INTERACTIONS">see Drug Interactions (7)</a></span>].</p>
<p><span class="Italics">Proton Pump Inhibitors:</span> A Phase 1, 2-period, cross-over study in 60 healthy postmenopausal female subjects evaluated the relative bioavailability of a single dose Risedronate sodium  35 mg delayed-release tablet taken after breakfast following 6 days of esomeprazole magnesium delayed release 40 mg capsules. On Day 6, esomeprazole 40 mg capsule was administered with 240 mL water one hour before breakfast and Risedronate sodium  35 mg tablet was administered with 240 mL water within 10 minutes after a standard breakfast. The C<span class="Sub">max</span> and AUC<span class="Sub">inf</span> of risedronate were increased by 60 percent and 22 percent, respectively, in presence of esomeprazole.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="section-12"></a><p></p>
<h1>
<span class="Bold">13</span>
		     
	<span class="Bold">NONCLINICAL TOXICOLOGY</span>
</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="section-12.1"></a><p></p>
<h2>
<span class="Bold">13.1</span>
		     
	<span class="Bold">Carcinogenesis, Mutagenesis, Impairment of Fertility</span>
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.1.1"></a><p></p>
<h3><span class="Underline">Carcinogenesis</span></h3>
<p class="First">In a 104-week carcinogenicity study, rats were administered daily oral doses up to approximately 8 times the human Paget’s disease dose of 30 mg/day. There were no significant drug-induced tumor findings in male or female rats. The high dose male group was terminated early in the study (Week 93) due to excessive toxicity, and data from this group were not included in the statistical evaluation of the study results. In an 80-week carcinogenicity study, mice were administered daily oral doses approximately 6.5 times the human dose. There were no significant drug-induced tumor findings in male or female mice.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.1.2"></a><p></p>
<h3><span class="Underline">Mutagenesis</span></h3>
<p class="First">Risedronate did not exhibit genetic toxicity in the following assays: <span class="Italics">In vitro</span> bacterial mutagenesis in <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span></span> and <span class="Italics">E. coli</span> (Ames assay), mammalian cell mutagenesis in CHO/HGPRT assay, unscheduled DNA synthesis in rat hepatocytes and an assessment of chromosomal aberrations <span class="Italics">in vivo</span> in rat bone marrow. Risedronate was positive in a chromosomal aberration assay in CHO cells at highly cytotoxic concentrations (greater than 675 mcg/mL, survival of 6% to 7%). When the assay was repeated at doses exhibiting appropriate cell survival (29%), there was no evidence of chromosomal damage.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.1.3"></a><p></p>
<h3><span class="Underline">Impairment of Fertility</span></h3>
<p class="First">In female rats, ovulation was inhibited at an oral dose approximately 5 times the human dose. Decreased implantation was noted in female rats treated with doses approximately 2.5 times the human dose. In male rats, testicular and epididymal <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span> and <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> were noted at approximately 13 times the human dose. <span class="product-label-link" type="condition" conceptid="438477" conceptname="Atrophy of testis">Testicular atrophy</span> was also noted in male rats after 13 weeks of treatment at oral doses approximately 5 times the human dose. There was moderate-to-severe spermatid maturation block after 13 weeks in male dogs at an oral dose approximately 8 times the human dose. These findings tended to increase in severity with increased dose and exposure time.</p>
<p>Dosing multiples provided above are based on the recommended human Paget’s disease dose of 30 mg/day and normalized using body surface area (mg/m<span class="Sup">2</span>). Actual doses were 24 mg/kg/day in rats, 32 mg/kg/day in mice, and 8, 16 and 40 mg/kg/day in dogs.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.2"></a><p></p>
<h2>
<span class="Bold">13.2</span>
		     
	<span class="Bold">Animal Toxicology and/or Pharmacology</span>
</h2>
<p class="First">Risedronate demonstrated potent anti-osteoclast, antiresorptive activity in ovariectomized rats and minipigs. Bone <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> and biomechanical strength were increased dose-dependently at daily oral doses up to 4 and 25 times the recommended human dose of 5 mg/day for rats and minipigs, respectively. Risedronate treatment maintained the positive correlation between BMD and bone strength and did not have a negative effect on bone structure or mineralization. In intact dogs, risedronate induced positive bone balance at the level of the bone remodeling unit at oral doses ranging from 0.5 to 1.5 times the human dose of 5 mg/day.</p>
<p>In dogs treated with an oral dose approximately 5 times the human dose of 5 mg/day, risedronate caused a delay in <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> healing of the radius. The observed delay in <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> healing is similar to other bisphosphonates. This effect did not occur at a dose approximately 0.5 times the human daily dose. </p>
<p>The Schenk rat assay, based on histologic examination of the epiphyses of growing rats after drug treatment, demonstrated that risedronate did not interfere with bone mineralization even at the highest dose tested, which was approximately 3500 times the lowest antiresorptive dose in this model (1.5 mcg/kg/day) and approximately 800 times the human dose of 5 mg/day. This indicates that Risedronate sodium  administered at the therapeutic dose is unlikely to induce <span class="product-label-link" type="condition" conceptid="432594" conceptname="Osteomalacia">osteomalacia</span>.</p>
<p>Dosing multiples provided above are based on the recommended human <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> dose of 5 mg/day and normalized using body surface area (mg/m<span class="Sup">2</span>). </p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-13"></a><p></p>
<h1>
<span class="Bold">14</span>
		     
	<span class="Bold">CLINICAL STUDIES</span>
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="_14_1_Treatment_of"></a><a name="section-13.1"></a><p></p>
<h2>
<span class="Bold">14.1</span>
		     
	<span class="Bold">Treatment of <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">Osteoporosis</span> in Postmenopausal Women</span>
</h2>
<p class="First">The efficacy of Risedronate sodium  35 mg once-a-week in the treatment of postmenopausal <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> was demonstrated in a randomized, double-blind, active-control trial of approximately 900 subjects. All patients in this study received supplemental calcium (1000 mg/day) and vitamin D (800 to 1000 international units/day). The primary efficacy endpoint was percent change in lumbar spine bone mineral density at 1 year. </p>
<p>Risedronate sodium  35 mg once-a-week administered after breakfast was shown to be non-inferior to risedronate sodium immediate-release 5 mg daily. Table 2 presents the primary efficacy analysis, percent change in lumbar spine BMD, in the intent-to-treat population with last observation carried forward (LOCF).</p>
<table>
<caption><span>Table 2 Lumbar Spine BMD - Percent Change from Baseline at Endpoint[a]</span></caption>
<col width="208">
<col width="160">
<col width="192">
<tbody class="Headless">
<tr class="First">
<td class="Lrule Toprule"></td>
<td class="Lrule Toprule" align="center">Risedronate sodium immediate-release <br>5 mg Daily</td>
<td class="Lrule Rrule Toprule" align="center">Risedronate sodium <br>35 mg Once-a-Week<br>Following Breakfast<br>
</td>
</tr>
<tr>
<td class="Lrule"></td>
<td class="Lrule" align="center">N = 307</td>
<td class="Lrule Rrule" align="center">N = 307</td>
</tr>
<tr>
<td class="Lrule Toprule">Primary Efficacy (LOCF)</td>
<td class="Lrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule">   n </td>
<td class="Lrule" align="center">270</td>
<td class="Lrule Rrule" align="center">261</td>
</tr>
<tr>
<td class="Lrule">   LS Mean (95% CI)</td>
<td class="Lrule" align="center">3.1* (2.7, 3.5)</td>
<td class="Lrule Rrule" align="center">3.3* (2.9, 3.7)</td>
</tr>
<tr>
<td class="Lrule"></td>
<td class="Lrule" align="center"></td>
<td class="Lrule Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule">   LS Mean Difference[b] (95% CI)</td>
<td class="Lrule" align="center"></td>
<td class="Lrule Rrule" align="center">-0.2 (-0.8, 0.3)</td>
</tr>
<tr class="Last"><td class="Lrule Rrule Toprule" colspan="3">N = number of intent-to-treat patients within specified treatment; n = number of patients with values at the visit.<br>*Indicates a statistically significant difference from baseline determined from 95% CI unadjusted for multiple comparisons.<br>LS = Least Squares<br>[a] at 1 year LOCF<br>[b] LS Mean Difference is 5 mg daily minus 35 mg weekly treatment.</td></tr>
</tbody>
</table>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fracture</span> efficacy </span><span class="Underline">with risedronate sodium immediate-release </span><span class="Underline">5 mg daily</span></p>
<p>The <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> efficacy of risedronate sodium immediate-release 5 mg daily in the treatment of postmenopausal <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> was demonstrated in 2 large, randomized, placebo-controlled, double-blind studies that enrolled a total of almost 4000 postmenopausal women under similar protocols. The Multinational study (VERT MN) (risedronate sodium immediate-release 5 mg daily, N = 408) was conducted primarily in Europe and Australia; a second study was conducted in North America (VERT NA) (risedronate sodium immediate-release 5 mg daily, N = 821). Patients were selected on the basis of radiographic evidence of previous <span class="product-label-link" type="condition" conceptid="4066995" conceptname="Fracture of vertebral column with spinal cord injury">vertebral fracture</span>, and therefore, had established disease. The average number of prevalent <span class="product-label-link" type="condition" conceptid="4066995" conceptname="Fracture of vertebral column with spinal cord injury">vertebral fractures</span> per patient at study entry was 4 in VERT MN, and 2.5 in VERT NA, with a broad range of baseline BMD levels. All patients in these studies received supplemental calcium 1000 mg/day. Patients with low 25-hydroxyvitamin D<span class="Sub">3</span> levels (approximately 40 nmol/L or less) also received 500 international units/day supplemental vitamin D.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1.1"></a><p></p>
<h3><span class="Underline">Effect on <span class="product-label-link" type="condition" conceptid="4066995" conceptname="Fracture of vertebral column with spinal cord injury">Vertebral Fractures</span></span></h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fractures</span> of previously undeformed vertebrae (new <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span>) and worsening of pre-existing <span class="product-label-link" type="condition" conceptid="4066995" conceptname="Fracture of vertebral column with spinal cord injury">vertebral fractures</span> were diagnosed radiographically; some of these <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> were also associated with symptoms (that is, clinical <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span>). Spinal radiographs were scheduled annually and prospectively planned analyses were based on the time to a patient’s first diagnosed <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span>. The primary endpoint for these studies was the incidence of new and worsening <span class="product-label-link" type="condition" conceptid="4066995" conceptname="Fracture of vertebral column with spinal cord injury">vertebral fractures</span> across the period of 0 to 3 years. Risedronate sodium immediate-release 5 mg daily significantly reduced the incidence of new and worsening <span class="product-label-link" type="condition" conceptid="4066995" conceptname="Fracture of vertebral column with spinal cord injury">vertebral fractures</span> and of new <span class="product-label-link" type="condition" conceptid="4066995" conceptname="Fracture of vertebral column with spinal cord injury">vertebral fractures</span> in both VERT NA and VERT MN at all time points (Table 3). The reduction in risk seen in the subgroup of patients who had 2 or more <span class="product-label-link" type="condition" conceptid="4066995" conceptname="Fracture of vertebral column with spinal cord injury">vertebral fractures</span> at study entry was similar to that seen in the overall study population.</p>
<table>
<caption><span>Table 3 The Effect of Risedronate sodium 5 mg Immediate-Release Daily on the Risk of <span class="product-label-link" type="condition" conceptid="4066995" conceptname="Fracture of vertebral column with spinal cord injury">Vertebral Fractures</span></span></caption>
<col width="128">
<col width="90">
<col width="110">
<col width="131">
<col width="139">
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule"></td>
<td class="Lrule Rrule Toprule" align="center" colspan="2">Proportion of Patients<br>with <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fracture</span> (%)<span class="Sup">a</span>
</td>
<td class="Lrule Rrule Toprule" colspan="2"></td>
</tr>
<tr>
<td class="Lrule Rrule"><span class="Bold"><br>VERT NA</span></td>
<td class="Lrule Rrule Toprule" align="center">Placebo<br>N = 678</td>
<td class="Lrule Rrule Toprule" align="center">Risedronate sodium<br>5 mg<br>N = 696</td>
<td class="Lrule Rrule Toprule" align="center">Absolute Risk<br>Reduction (%)</td>
<td class="Lrule Rrule Toprule" align="center">Relative Risk<br>Reduction (%)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">New and Worsening</td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule">  0 to 1 Year</td>
<td class="Lrule Rrule" align="center">7.2</td>
<td class="Lrule Rrule" align="center">3.9</td>
<td class="Lrule Rrule" align="center">3.3</td>
<td class="Lrule Rrule" align="center">49</td>
</tr>
<tr>
<td class="Lrule Rrule">  0 to 2 Years</td>
<td class="Lrule Rrule" align="center">12.8</td>
<td class="Lrule Rrule" align="center">8.0</td>
<td class="Lrule Rrule" align="center">4.8</td>
<td class="Lrule Rrule" align="center">42</td>
</tr>
<tr>
<td class="Lrule Rrule">  0 to 3 Years</td>
<td class="Lrule Rrule" align="center">18.5</td>
<td class="Lrule Rrule" align="center">13.9</td>
<td class="Lrule Rrule" align="center">4.6</td>
<td class="Lrule Rrule" align="center">33</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">New</td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule">  0 to 1 Year</td>
<td class="Lrule Rrule" align="center">6.4</td>
<td class="Lrule Rrule" align="center">2.4</td>
<td class="Lrule Rrule" align="center">4.0</td>
<td class="Lrule Rrule" align="center">65</td>
</tr>
<tr>
<td class="Lrule Rrule">  0 to 2 Years</td>
<td class="Lrule Rrule" align="center">11.7</td>
<td class="Lrule Rrule" align="center">5.8</td>
<td class="Lrule Rrule" align="center">5.9</td>
<td class="Lrule Rrule" align="center">55</td>
</tr>
<tr>
<td class="Lrule Rrule">  0 to 3 Years</td>
<td class="Lrule Rrule" align="center">16.3</td>
<td class="Lrule Rrule" align="center">11.3</td>
<td class="Lrule Rrule" align="center">5.0</td>
<td class="Lrule Rrule" align="center">41</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule"><span class="Bold"><br>VERT MN</span></td>
<td class="Lrule Rrule Toprule" align="center">Placebo<br>N = 346</td>
<td class="Lrule Rrule Toprule" align="center">Risedronate sodium<br>5 mg<br>N = 344</td>
<td class="Lrule Rrule Toprule" align="center">Absolute Risk<br>Reduction (%)</td>
<td class="Lrule Rrule Toprule" align="center">Relative Risk<br>Reduction (%)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">New and Worsening</td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule">  0 to 1 Year</td>
<td class="Lrule Rrule" align="center">15.3</td>
<td class="Lrule Rrule" align="center">8.2</td>
<td class="Lrule Rrule" align="center">7.1</td>
<td class="Lrule Rrule" align="center">50</td>
</tr>
<tr>
<td class="Lrule Rrule">  0 to 2 Years</td>
<td class="Lrule Rrule" align="center">28.3</td>
<td class="Lrule Rrule" align="center">13.9</td>
<td class="Lrule Rrule" align="center">14.4</td>
<td class="Lrule Rrule" align="center">56</td>
</tr>
<tr>
<td class="Lrule Rrule">  0 to 3 Years</td>
<td class="Lrule Rrule" align="center">34.0</td>
<td class="Lrule Rrule" align="center">21.8</td>
<td class="Lrule Rrule" align="center">12.2</td>
<td class="Lrule Rrule" align="center">46</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">New</td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
<td class="Lrule Rrule Toprule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule">  0 to 1 Year</td>
<td class="Lrule Rrule" align="center">13.3</td>
<td class="Lrule Rrule" align="center">5.6</td>
<td class="Lrule Rrule" align="center">7.7</td>
<td class="Lrule Rrule" align="center">61</td>
</tr>
<tr>
<td class="Lrule Rrule">  0 to 2 Years</td>
<td class="Lrule Rrule" align="center">24.7</td>
<td class="Lrule Rrule" align="center">11.6</td>
<td class="Lrule Rrule" align="center">13.1</td>
<td class="Lrule Rrule" align="center">59</td>
</tr>
<tr>
<td class="Lrule Rrule">  0 to 3 Years</td>
<td class="Lrule Rrule" align="center">29.0</td>
<td class="Lrule Rrule" align="center">18.1</td>
<td class="Lrule Rrule" align="center">10.9</td>
<td class="Lrule Rrule" align="center">49</td>
</tr>
<tr class="Last"><td class="Lrule Rrule Toprule" colspan="5">
<span class="Sup">a</span>Calculated by Kaplan-Meier methodology.</td></tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1.2"></a><p></p>
<h3><span class="Underline">Effect on <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">Osteoporosis</span>-Related Nonvertebral <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fractures</span></span></h3>
<p class="First">In VERT MN and VERT NA, a prospectively planned efficacy endpoint was defined consisting of all radiographically confirmed <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> of skeletal sites accepted as associated with <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>. <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fractures</span> at these sites were collectively referred to as <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>-related nonvertebral <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span>. Risedronate sodium immediate-release 5 mg daily significantly reduced the incidence of nonvertebral <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>-related <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> over 3 years in VERT NA (8% versus 5%; relative risk reduction 39%) and reduced the <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> incidence in VERT MN from 16% to 11%. There was a significant reduction from 11% to 7% when the studies were combined, with a corresponding 36% reduction in relative risk. Figure 1 shows the overall results as well as the results at the individual skeletal sites for the combined studies.</p>
<p><img alt="Figure 1: Nonvertebral <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">Osteoporosis</span>-Related <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fractures</span> Cumulative Incidence Over 3 Years Combined VERT MN and VERT NA" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ef2dbc86-b4f5-4990-a83f-0b121cfe2ec1&amp;name=risedronate-sodium-delayed-release-tablets-02.jpg"></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1.3"></a><p></p>
<h3><span class="Underline">Histology/Histomorphometry</span></h3>
<p class="First">Bone biopsies from 110 postmenopausal women were obtained at endpoint in the VERT NA study. Patients had received placebo or daily risedronate sodium immediate-release (2.5 mg or 5 mg) for 2 to 3 years. Histologic evaluation (N = 103) showed no <span class="product-label-link" type="condition" conceptid="432594" conceptname="Osteomalacia">osteomalacia</span>, impaired bone mineralization, or other adverse effects on bone in risedronate sodium immediate-release treated women. These findings demonstrate that bone formed during risedronate sodium immediate-release administration is of normal quality. The histomorphometric parameter mineralizing surface, an index of bone turnover, was assessed based upon baseline and post-treatment biopsy samples from 21 treated with placebo and 23 patients treated with risedronate sodium immediate-release 5 mg daily. Mineralizing surface decreased moderately in risedronate sodium immediate-release treated patients (median percent change: placebo, -21%; risedronate sodium immediate-release 5 mg daily, -74%), consistent with the known effects of treatment on bone turnover.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1.4"></a><p></p>
<h3><span class="Underline">Effect on Height</span></h3>
<p class="First">In the two 3-year <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> treatment studies, standing height was measured yearly by stadiometer. Both risedronate sodium immediate-release 5 mg daily and placebo-treated groups lost height during the studies. Patients who received risedronate sodium immediate-release 5 mg daily had a statistically significantly smaller loss of height than those who received placebo. In VERT MN, the median annual height change was -2.4 mm/yr in the placebo group compared to -1.3 mm/yr in the risedronate sodium immediate-release 5 mg daily group. In VERT NA, the median annual height change was -1.1 mm/yr in the placebo group compared to -0.7 mm/yr in the risedronate sodium immediate-release 5 mg daily group.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1.5"></a><p></p>
<h3><span class="Underline">Effect on Bone Mineral Density</span></h3>
<p class="First">The results of 4 randomized, placebo-controlled trials in women with postmenopausal <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> (VERT MN, VERT NA, BMD MN, BMD NA) demonstrate that risedronate sodium immediate-release 5 mg daily increases BMD at the spine, hip, and wrist compared to the effects seen with placebo. Table 4 displays the significant increases in BMD seen at the lumbar spine, femoral neck, femoral trochanter, and midshaft radius in these trials compared to placebo. In both VERT studies (VERT MN and VERT NA), risedronate sodium immediate-release 5 mg daily produced increases in lumbar spine BMD that were progressive over the 3 years of treatment, and were statistically significant relative to baseline and to placebo at 6 months and at all later time points.</p>
<table>
<caption><span>Table 4 Mean Percent Increase in BMD from Baseline in Patients Taking Risedronate sodium Immediate-Release 5 mg or Placebo at Endpoint<span class="Sup">a</span></span></caption>
<col width="103">
<col width="60">
<col width="60">
<col width="60">
<col width="60">
<col width="60">
<col width="60">
<col width="60">
<col width="60">
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule"></td>
<td class="Lrule Rrule Toprule" align="center" colspan="2">VERT MN<span class="Sup">b</span>
</td>
<td class="Lrule Rrule Toprule" align="center" colspan="2">VERT NA<span class="Sup">b</span>
</td>
<td class="Lrule Toprule" align="center" colspan="2">BMD MN<span class="Sup">c</span>
</td>
<td class="Rrule Toprule" align="center" colspan="2">BMD NA<span class="Sup">c</span>
</td>
</tr>
<tr>
<td class="Lrule Rrule"></td>
<td class="Lrule Toprule">Placebo<br>N = 323</td>
<td class="Rrule Toprule">5 mg<br>N = 323</td>
<td class="Lrule Toprule">Placebo<br>N = 599</td>
<td class="Rrule Toprule">5 mg<br>N = 606</td>
<td class="Lrule Toprule">Placebo<br>N = 161</td>
<td class="Toprule">5 mg<br>N = 148</td>
<td class="Toprule">Placebo<br>N = 191</td>
<td class="Rrule Toprule">5 mg<br>N = 193</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">Lumbar Spine</td>
<td class="Lrule Toprule">1.0</td>
<td class="Rrule Toprule">6.6</td>
<td class="Lrule Toprule">0.8</td>
<td class="Rrule Toprule">5.0</td>
<td class="Lrule Toprule">0.0</td>
<td class="Rrule Toprule">4.0</td>
<td class="Lrule Toprule">0.2</td>
<td class="Rrule Toprule">4.8</td>
</tr>
<tr>
<td class="Lrule Rrule">Femoral Neck</td>
<td class="Lrule">-1.4</td>
<td class="Rrule">1.6</td>
<td class="Lrule">-1.0</td>
<td class="Rrule">1.4</td>
<td class="Lrule">-1.1</td>
<td class="Rrule">1.3</td>
<td class="Lrule">0.1</td>
<td class="Rrule">2.4</td>
</tr>
<tr>
<td class="Lrule Rrule">Femoral Trochanter</td>
<td class="Lrule">-1.9</td>
<td class="Rrule">3.9</td>
<td class="Lrule">-0.5</td>
<td class="Rrule">3.0</td>
<td class="Lrule">-0.6</td>
<td class="Rrule">2.5</td>
<td class="Lrule">1.3</td>
<td class="Rrule">4.0</td>
</tr>
<tr>
<td class="Lrule Rrule">Midshaft Radius</td>
<td class="Lrule">-1.5*</td>
<td class="Rrule">0.2*</td>
<td class="Lrule">-1.2*</td>
<td class="Rrule">0.1*</td>
<td class="Lrule Rrule" align="center" colspan="2">ND</td>
<td class="Lrule Rrule" align="center" colspan="2">ND</td>
</tr>
<tr class="Last"><td class="Lrule Rrule Toprule" colspan="9">
<span class="Sup">a</span>The endpoint value is the value at the study's last time point for all patients who had BMD measured at that time; otherwise the last post-baseline BMD value prior to the study's last time point is used.<br><span class="Sup">b</span>The duration of the studies was 3 years.<br><span class="Sup">c</span>The duration of the studies was 1.5 to 2 years.<br>*BMD of the midshaft radius was measured in a subset of centers in VERT MN (placebo, N = 222;<br>5 mg, N = 214) and VERT NA (placebo, N = 310; 5 mg, N = 306).<br>ND = analysis not done</td></tr>
</tbody>
</table>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-14"></a><p></p>
<h1>
<span class="Bold">16</span>
		     
	<span class="Bold">HOW SUPPLIED/STORAGE AND HANDLING</span>
</h1>
<p class="First">Risedronate sodium delayed-release tablets are:</p>
<p>35 mg, yellow, oval-shaped, and engraved with EC 35 on one side.</p>
<p>NDC 0591-3876-04
		     
	Dose pack of 4 tablets</p>
<p>Store at controlled room temperature 20° to 25° C (68° to 77° F) [see USP].</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="_17_PATIENT_COUNSELING"></a><a name="section-15"></a><p></p>
<h1>
<span class="Bold">17</span>
		     
	<span class="Bold">PATIENT COUNSELING INFORMATION</span>
</h1>
<p class="First">See FDA-approved patient labeling (Medication Guide)</p>
<p>Instruct patients to read the Medication Guide before starting therapy with Risedronate sodium  and to re-read it each time the prescription is renewed.</p>
<p>Instruct patients that Risedronate sodium and Actonel contain the same active ingredient and if they are taking Actonel, they should not take Risedronate sodium  [<span class="Italics"><a href="#_5_1_Drug_Products">see Warnings and Precautions (5.1)</a></span>].</p>
<p>Instruct patients to pay particular attention to the dosing instructions as clinical benefits may be compromised by failure to take the drug according to instructions. </p>
<p>Instruct patients to take Risedronate sodium  in the morning, while in an upright position (sitting or standing) with at least 4 ounces of plain water immediately following breakfast. Risedronate sodium should not be taken before breakfast. </p>
<p>Instruct patients to swallow Risedronate sodium  tablets whole. Patients should not chew, cut, or crush the tablet because of a potential for oropharyngeal irritation, and because the tablet coating is an important part of the delayed-release formulation. Patients should not lie down for 30 minutes after taking the medication. </p>
<p>Instruct patients that if they develop symptoms of esophageal disease (such as difficulty or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> upon swallowing, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">retrosternal pain</span> or severe persistent or worsening <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span>) they should consult their physician before continuing Risedronate sodium  [<span class="Italics"><a href="#_5_2__Upper">see Warnings and Precautions (5.2)</a></span>].</p>
<p>If a dose of Risedronate sodium  35 mg once-a-week is missed, instruct the patient to take one tablet on the morning after they remember and return to taking one tablet once-a-week, as originally scheduled on their chosen day. Patients should not take 2 tablets on the same day.</p>
<p>Instruct patients to take supplemental calcium and vitamin D if dietary intake is inadequate [<span class="Italics">see</span> <span class="Italics"><a href="#_5_3_Mineral_Metabolism">Warnings and Precautions (5.3</a></span><span class="Italics">)</span>]. </p>
<p>Instruct patients to take calcium supplements, antacids, magnesium-based supplements or laxatives, and iron preparations at a different time of the day because they interfere with the absorption of Risedronate sodium . </p>
<p>Remind patients to give all of their healthcare providers an accurate medication history. Instruct patients to tell all of their healthcare providers that they are taking Risedronate sodium . Patients should be instructed that any time they have a medical problem they think may be from Risedronate sodium  they should talk to their doctor. </p>
<p>Manufactured by:<br>Norwich Pharmaceuticals, Inc.<br>North Norwich, NY  13814</p>
<p>Distributed by:<br>Actavis Pharma, Inc.<br>Parsippany, NJ 07054 USA</p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="section-16"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Medication Guide</span><br><span class="Bold">Risedronate sodium </span><br><span class="Bold">d</span><span class="Bold">elayed</span><span class="Bold">-</span><span class="Bold">release tablets </span></p>
<p>Read this Medication Guide that comes with Risedronate sodium before you start taking it and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking with your doctor about your medical condition or your treatment. Talk to your doctor if you have any questions about Risedronate sodium, there may be new information about it. </p>
<p><span class="Bold">What is the most important information I should know about </span><span class="Bold">Risedronate sodium</span><span class="Bold">?</span></p>
<p><span class="Bold">Risedronate sodium</span><span class="Bold"> can cause serious side effects including</span>:</p>
<ol class="Arabic">
<li>Esophagus problems<br>
</li>
<li>Low calcium levels in your blood (<span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>)<br>
</li>
<li>Severe jaw bone problems (<span class="product-label-link" type="condition" conceptid="77650" conceptname="Aseptic necrosis of bone">osteonecrosis</span>)<br>
</li>
<li>Bone, joint, or <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span><br>
</li>
<li>Unusual thigh bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span></li>
</ol>
<p><span class="Bold">1. Esophagus problems.</span></p>
<p><span class="Bold">Some people who take </span><span class="Bold">Risedronate sodium</span><span class="Bold"> may develop problems in the esophagus (the tube that connects the mouth and the stomach). These problems include irritation, <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, or <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> of the esophagus which may sometimes bleed.</span></p>
<ul class="Disc">
<li>
<span class="Bold">It is important that you take </span><span class="Bold">Risedronate sodium</span><span class="Bold"> exactly as prescribed to help lower your chance of getting esophagus problems. (See the section “How should I take </span><span class="Bold">Risedronate sodium</span><span class="Bold">??)</span><br>
</li>
<li>
<span class="Bold">Stop taking </span><span class="Bold">Risedronate sodium </span><span class="Bold">and call your doctor right away if you get <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, new or worsening <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span>, or have trouble or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> when you swallow.</span>
</li>
</ul>
<p><span class="Bold">2. Low calcium levels in your blood (<span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>).</span></p>
<p>Risedronate sodium  may lower the calcium levels in your blood. If you have low blood calcium before you start taking Risedronate sodium , it may get worse during treatment. Your low blood calcium must be treated before you take Risedronate sodium . Most people with low blood calcium levels do not have symptoms, but some people may have symptoms. Call your doctor right away if you have symptoms of low blood calcium such as:</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Spasms</span>, <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">twitches</span>, or <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span> in your muscles<br>
</li>
<li><span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">Numbness</span> or <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span> in your fingers, toes, or around your mouth</li>
</ul>
<p>Your doctor may prescribe calcium and vitamin D to help prevent low calcium levels in your blood, while you are taking Risedronate sodium . Take calcium and vitamin D as your doctor tells you to.</p>
<p><span class="Bold">3. Severe jaw bone problems (<span class="product-label-link" type="condition" conceptid="77650" conceptname="Aseptic necrosis of bone">osteonecrosis</span>).</span></p>
<p>Severe jaw bone problems may happen when you take Risedronate sodium . Your doctor should examine your mouth before you start Risedronate sodium . Your doctor may tell you to see your dentist before you start Risedronate sodium . It is important for you to practice good mouth care during treatment with Risedronate sodium .</p>
<p><span class="Bold">4. Bone, joint, or <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>.</span></p>
<p>Some people who take Risedronate sodium  develop severe bone, joint, or <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>.</p>
<p><span class="Bold">5. Unusual thigh bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span>.</span></p>
<p>Some people have developed unusual <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> in their thigh bone. Symptoms of a <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> may include new or unusual <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in your hip, groin, or thigh.</p>
<p><span class="Bold">Call your doctor right away if you have any of these side effects.</span></p>
<p><span class="Bold">What is </span><span class="Bold">Risedronate sodium</span><span class="Bold">?</span></p>
<p>Risedronate sodium is a prescription medicine used to treat <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> in women after <span class="product-label-link" type="condition" conceptid="4059477" conceptname="Menopause">menopause</span>.</p>
<p>It is not known how long Risedronate sodium  works for the treatment and prevention of <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>. You should see your doctor regularly to determine if Risedronate sodium is still right for you.</p>
<p>Risedronate sodium is not for use in children.</p>
<p><span class="Bold">Who should not take </span><span class="Bold">Risedronate sodium </span><span class="Bold">?</span></p>
<p><span class="Bold">Do not take </span><span class="Bold">Risedronate sodium</span><span class="Bold"> </span><span class="Bold">if you</span><span class="Bold">:</span></p>
<ul class="Disc">
<li>Have certain problems with your esophagus, the tube that connects your mouth and stomach <br>
</li>
<li>Cannot sit or stand up for at least 30 minutes<br>
</li>
<li>Have low blood calcium (<span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>)<br>
</li>
<li>Are allergic to any of the other ingredients in Risedronate sodium .<span class="Bold"> </span>See the end of this leaflet for a complete list of ingredients in Risedronate sodium .</li>
</ul>
<p><span class="Bold">What should I tell my healthcare provider before taking </span><span class="Bold">Risedronate sodium</span><span class="Bold">?</span></p>
<p><span class="Bold">Before you take </span><span class="Bold">Risedronate sodium</span><span class="Bold">, t</span><span class="Bold">ell your </span><span class="Bold">healthcare provider </span><span class="Bold">if</span><span class="Bold"> you</span><span class="Bold">:</span></p>
<ul class="Disc">
<li>Have problems swallowing<br>
</li>
<li>Have stomach or digestive problems<br>
</li>
<li>Have low blood calcium<br>
</li>
<li>Plan to have dental surgery or teeth removed<br>
</li>
<li>Have kidney problems<br>
</li>
<li>Have been told you have trouble absorbing mineral in your stomach or intestines (<span class="product-label-link" type="condition" conceptid="194993" conceptname="Intestinal malabsorption">malabsorption syndrome</span>)<br>
</li>
<li>Are pregnant or plan to become pregnant. It is not known if Risedronate sodium can harm your unborn baby.<br>
</li>
<li>Are breastfeeding or plan to breastfeed. It is not known if Risedronate sodium passes into your breast milk and may harm your baby. You and your doctor should decide if you will take Risedronate sodium  or breastfeed. You should not do both.</li>
</ul>
<p><span class="Bold">Tell your doctor </span><span class="Bold">about all the medicines you take, </span>including prescription and non-prescription medicines, vitamins and herbal supplements. Certain medicines may affect how Risedronate sodium  works.</p>
<p><span class="Bold">Especially tell your doctor if you take</span>:</p>
<ul class="Disc">
<li>Actonel<span class="Sup">®</span> or other medicines to treat <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span><br>
</li>
<li>calcium supplements<br>
</li>
<li>antacids<br>
</li>
<li>laxatives<br>
</li>
<li>iron supplements  </li>
</ul>
<p>Ask your doctor or pharmacist for a list of these medications, if you are not sure.</p>
<p>Know the medicines you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine. </p>
<p><span class="Bold">How should I take </span><span class="Bold">Risedronate sodium </span><span class="Bold">?</span></p>
<ul class="Disc">
<li>Take Risedronate sodium exactly as your doctor tells you.<br>
</li>
<li>Take Risedronate sodium<span class="Bold"> </span>1 time a week <span class="Bold">right after breakfast</span>. Choose a day of the week to take Risedronate sodium that best fits your schedule.<br>
</li>
<li>Take Risedronate sodium with at least 4 ounces (about 1-half cup) of plain water. <br>
</li>
<li>Swallow Risedronate sodium tablets whole. <span class="Bold">Do not chew, cut, or crush </span>Risedronate sodium tablets before swallowing. If you cannot swallow Risedronate sodium tablets whole, tell your doctor. You may need a different medicine.</li>
</ul>
<p>After swallowing Risedronate sodium wait at least 30 minutes:</p>
<ul class="Disc">
<li>Before you lie down. You may sit, stand or walk, and do normal activities like reading.<br>
</li>
<li>Before you take other medicines, including antacids, calcium, and other supplements and vitamins.</li>
</ul>
<p><span class="Bold">Do not lie down for at least 30 minutes after you take </span><span class="Bold">Risedronate sodium </span><span class="Bold">.</span></p>
<p>If you miss your weekly Risedronate sodium dose, take Risedronate sodium  the morning after you remember then return to your normal schedule. Do not take 2 doses at the same time.</p>
<p>You should take calcium and vitamin D as directed by your doctor.</p>
<p>If you take too much Risedronate sodium, call your doctor. Do not try to vomit. Do not lie down.</p>
<p><span class="Bold">What are the possible side effects of </span><span class="Bold">Risedronate sodium</span><span class="Bold">?</span></p>
<p>Risedronate sodium may cause serious side effects:</p>
<ul class="Disc"><li>See <span class="Bold">“What is the most important information I should know about Risedronate sodium?</span>.</li></ul>
<p>The most common side effects of Risedronate sodium include:</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> <br>
</li>
<li>flu-like symptoms<br>
</li>
<li><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span> <br>
</li>
<li>back and <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span><br>
</li>
<li><span class="product-label-link" type="condition" conceptid="4012224" conceptname="Upset stomach">upset stomach</span> <br>
</li>
<li>stomach area (abdominal) <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></li>
</ul>
<p>You may get <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>, such as <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your face, lips, tongue, or throat.</p>
<p>Tell your doctor if you have any side effect that bothers you or that does not go away.</p>
<p>These are not all the possible side effects of Risedronate sodium. For more information, ask your doctor or pharmacist.  </p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store </span><span class="Bold">Risedronate sodium</span><span class="Bold">?</span></p>
<ul class="Disc"><li>Store Risedronate sodium between 68° F to 77° F (20° C to 25° C).</li></ul>
<p><span class="Bold">Keep </span><span class="Bold">Risedronate sodium </span><span class="Bold"> </span><span class="Bold">and all medicines out of the reach of children.</span></p>
<p><span class="Bold">General information about </span><span class="Bold">the safe and effective use of </span><span class="Bold">Risedronate sodium </span><span class="Bold"> </span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information Leaflet. Do not use Risedronate sodium for a condition for which it was not prescribed. Do not give Risedronate sodium to other people, even if they have the same symptoms you have. It may harm them.</p>
<p>This Medication Guide summarizes the most important information about Risedronate sodium. If you would like more information, talk with your doctor. You can ask your pharmacist or doctor for information about Risedronate sodium that is written for health professionals.  </p>
<p>For more information, go to www.actavis.com or call 1-800-272-5525<a href="#"></a>.  </p>
<p><span class="Bold">What are the ingredients </span><span class="Bold">in</span><span class="Bold"> </span><span class="Bold">Risedronate sodium</span><span class="Bold">?</span></p>
<p>Active ingredient: risedronate sodium</p>
<p>Inactive ingredients: Edetate disodium, ferric oxide yellow, magnesium stearate, methacrylic acid copolymer, polysorbate 80, silicified microcrystalline cellulose (ProSolv SMCC90), simethicone, sodium starch glycolate, stearic acid, talc, and triethyl citrate.</p>
<p>This Medication Guide has been approved by the U.S. Food and Drug Administration.</p>
<p>Manufactured by:<br>Norwich Pharmaceuticals, Inc.<br>North Norwich, NY  13814</p>
<p>Distributed by:<br>Actavis Pharma, Inc.<br>Parsippany, NJ 07054 USA</p>
<p>Content Updated:  March 2015</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<h1><span class="Bold">PRINCIPAL DISPLAY PANEL</span></h1>
<p class="First"><span class="Bold">NDC 0591-3876-04</span><span class="Bold"><br>Risedronate Sodium</span><span class="Bold"><br>Delayed-Release Tablets</span><span class="Bold"><br>35 mg</span><span class="Bold"><br>Once-a-week</span></p>
<p><img alt="PRINCIPAL DISPLAY PANEL
NDC 0591-3876-04
Risedronate Sodium
Delayed-Release Tablets
35 mg
Once-a-week
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ef2dbc86-b4f5-4990-a83f-0b121cfe2ec1&amp;name=risedronate-sodium-delayed-release-tablets-03.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>RISEDRONATE SODIUM 		
					</strong><br><span class="contentTableReg">risedronate sodium tablet, delayed release</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0591-3876</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>RISEDRONATE SODIUM HEMI-PENTAHYDRATE</strong> (RISEDRONIC ACID) </td>
<td class="formItem">RISEDRONATE SODIUM ANHYDROUS</td>
<td class="formItem">30.1 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>RISEDRONATE SODIUM MONOHYDRATE</strong> (RISEDRONIC ACID) </td>
<td class="formItem">RISEDRONATE SODIUM ANHYDROUS</td>
<td class="formItem">4.9 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>EDETATE DISODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STEARIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TRIETHYL CITRATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">12mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">EC;35</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0591-3876-04</td>
<td class="formItem">4  in 1 DOSE PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022560</td>
<td class="formItem">12/01/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Actavis Pharma, Inc.
							(119723554)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 4/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>aa3e091a-7bfe-4e74-9aa1-0cbfa9ab7e23</div>
<div>Set id: ef2dbc86-b4f5-4990-a83f-0b121cfe2ec1</div>
<div>Version: 1</div>
<div>Effective Time: 20150430</div>
</div>
</div> <div class="DistributorName">Actavis Pharma, Inc.</div></p>
</body></html>
